<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
    <id>https://macwaneric.github.io/cancer.rss.feed/index.html</id>
    <title>CancerFeed</title>
    <updated>2023-01-07T01:00:42.036Z</updated>
    <generator>osmosfeed 1.15.1</generator>
    <link rel="alternate" href="https://macwaneric.github.io/cancer.rss.feed/index.html"/>
    <link rel="self" href="https://macwaneric.github.io/cancer.rss.feed/feed.atom"/>
    <entry>
        <title type="html"><![CDATA[Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report]]></title>
        <id>pubmed:36604730</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604730/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this patient, longitudinal WES analysis revealed a sequential and cumulative pattern of genetic alterations, where germline and nevi somatic events contributed early to its rapid clinical progression. In this case report, we found tumor-associated nevi as genetically heterogeneous precursor entities, in which potential prognostic biomarkers should be studied prospectively.]]></summary>
        <author>
            <name>Ana Mordoh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis]]></title>
        <id>pubmed:36604421</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36604421/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 pathogenic variants. Here, we perform whole-genome sequence (WGS) analysis of tumors from 22 patients with TP53 germline pathogenic variants. We observe somatic mutations affecting Wnt, PI3K/AKT signaling, epigenetic modifiers and homologous recombination genes as well as mutational signatures associated with prior chemotherapy. We identify near-ubiquitous early loss of heterozygosity of TP53,...]]></summary>
        <author>
            <name>Nicholas Light</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment]]></title>
        <id>pubmed:36599826</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36599826/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and...]]></summary>
        <author>
            <name>Kelly von Beck</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></title>
        <id>pubmed:36598417</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36598417/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multi-regional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy number...]]></summary>
        <author>
            <name>Isidro Cortes-Ciriano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis]]></title>
        <id>pubmed:36596806</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36596806/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[During embryogenesis, haematopoietic and endothelial lineages emerge closely in time and space. It is thought that the first blood and endothelium derive from a common clonal ancestor, the haemangioblast. However, investigation of candidate haemangioblasts in vitro revealed the capacity for mesenchymal differentiation, a feature more compatible with an earlier mesodermal precursor. To date, no evidence for an in vivo haemangioblast has been discovered. Using single cell RNA-Sequencing and in...]]></summary>
        <author>
            <name>C Biben</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:36595120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36595120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis is a prevalent disease associated with all-cause death. Not only because it can be a precancerous lesion of blood system diseases but also has a strong association with cardiovascular disease. A narrow term, clonal hematopoiesis of indeterminate potential (CHIP), was proposed by Steensma et al. [1] to describe individuals with detectable somatic clonal mutations in their genes in blood or bone marrow but without a diagnosis of hematological disease or unexplained cytopenia....]]></summary>
        <author>
            <name>Xiongkai Yu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation - the perpetual cycle]]></title>
        <id>pubmed:36593155</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36593155/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired genetic or cytogenetic alterations in a blood stem cell that confer clonal fitness promote its relative expansion leading to clonal hematopoiesis (CH). Despite a largely intact hematopoietic output, CH is associated with a heightened risk of progression to hematologic malignancies and with non-hematologic health manifestations, including cardiovascular disease and overall mortality. We focus on the evidence for the role of inflammation in establishing, maintaining and reciprocally being...]]></summary>
        <author>
            <name>Serine Avagyan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36587837</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587837/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Evidence on the Role of Clonal Hematopoiesis of Indeterminate Potential in Chronic Kidney Disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Evidence on the Role of Clonal Hematopoiesis of Indeterminate Potential in Chronic Kidney Disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Evidence on the Role of Clonal Hematopoiesis of Indeterminate Potential in Chronic Kidney Disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Evidence on the Role of Clonal Hematopoiesis of Indeterminate Potential in Chronic Kidney Disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Evidence on the Role of Clonal Hematopoiesis of Indeterminate Potential in Chronic Kidney Disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Evidence on the Role of Clonal Hematopoiesis of Indeterminate Potential in Chronic Kidney Disease]]></title>
        <id>pubmed:36586535</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36586535/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic kidney disease (CKD) was responsible for 1.2 million deaths globally in 2016. Despite the large and growing burden of CKD, treatment options are limited and generally only preserve kidney function. Characterizing molecular precursors to incident and progressive CKD could point to critically needed prevention and treatment strategies. Clonal hematopoiesis of indeterminate potential (CHIP) is typically characterized by the clonal expansion of blood cells carrying somatic mutations in...]]></summary>
        <author>
            <name>Zhijie Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell resolved ploidy and chromosomal aberrations in nonalcoholic steatohepatitis-(NASH) induced hepatocellular carcinoma and its precursor lesions]]></title>
        <id>pubmed:36587184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36587184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nonalcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC) and its precursor, nonalcoholic fatty liver disease (NAFLD) are an unmet health issue due to widespread obesity. We assessed copy number changes of genes associated with hepatocarcinogenesis and oxidative pathways at a single-cell level. Eleven patients with NASH-HCC and 11 patients with NAFLD were included. Eight probes were analyzed using multiplex interphase fluorescence in situ hybridization (miFISH), single-cell...]]></summary>
        <author>
            <name>Juliane Friemel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between peripheral blood cytopenia and cancer mortality: A race-specific risk factor for cancer death]]></title>
        <id>pubmed:36583503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36583503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this large, observational biracial prospective study, cytopenia was a risk factor for cancer death, with stronger association in Black than White people. Though race impacted the association of cytopenia with cancer mortality, cytopenia was not a mediator of the racial disparity in cancer mortality.]]></summary>
        <author>
            <name>Diego A Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early development of esophageal squamous cell cancer: Stem cells, cellular origins and early clone evolution]]></title>
        <id>pubmed:36584935</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36584935/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Esophageal squamous cell carcinoma (ESCC), a highly malignant cancer with poor prognosis, is an example of the classical view of cancer development based on stem cell origin and multistep progression. In the past five years, the applications of large-scale sequencing and single-cell sequencing have expanded to human esophageal normal tissues and precancerous lesions, which, coupled with the application of transgenic lineage tracing technology in mouse models, has provided a more comprehensive...]]></summary>
        <author>
            <name>Guobin Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting TGF- signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction]]></title>
        <id>pubmed:36578789</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36578789/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence of relapsed and/or refractory MM (RRMM) is provoked through clonal evolution of malignant plasma cells that harbor genomic, metabolic and proteomic perturbations. For most patients, relapsed disease remains a major cause of overall mortality. Transforming growth factors (TGFs) have pleiotropic effects that regulate...]]></summary>
        <author>
            <name>Priyanka S Rana</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?]]></title>
        <id>pubmed:36570410</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36570410/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies are the detection of molecular information in fluids from patients with cancer. In colorectal cancer (CRC), the most promising liquid biopsy strategy is the use of circulating tumor DNA (ctDNA) from plasma. In early-stage CRC, the potential for ctDNA to impact care stems from the detection of minimal residual disease (MRD) to guide adjuvant therapy after curative intent treatment and in identifying recurrences during surveillance. As for any new diagnostic test, ctDNA assays must...]]></summary>
        <author>
            <name>Joao Paulo Solar Vasconcelos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort]]></title>
        <id>pubmed:36566538</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36566538/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Vitamin C is an essential vitamin that acts as a co-factor for many enzymes involved in epigenetic regulation in humans. Low vitamin C levels in hematopoietic stem cells (HSC) promote self-renewal and vitamin C supplementation retards leukaemogenesis in vitamin C-deficient mouse models. Studies on vitamin C levels in patients with myeloid malignancies are limited. We thus conducted a retrospective analysis on a prospective cohort of patients with myeloid malignancies on whom plasma vitamin C...]]></summary>
        <author>
            <name>Naveen Premnath</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-Time Characterization of Clonal Fate Decisions in Complex Leukemia Samples by Fluorescent Genetic Barcoding]]></title>
        <id>pubmed:36552809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36552809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal heterogeneity in acute myeloid leukemia (AML) forms the basis for treatment failure and relapse. Attempts to decipher clonal evolution and clonal competition primarily depend on deep sequencing approaches. However, this prevents the experimental confirmation of the identified disease-relevant traits on the same cell material. Here, we describe the development and application of a complex fluorescent genetic barcoding (cFGB) lentiviral vector system for the labeling and subsequent...]]></summary>
        <author>
            <name>Tobias Maetzig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma]]></title>
        <id>pubmed:36551283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Molecular heterogeneity has great significance in the disease biology of multiple myeloma (MM). Thus, the analysis combined single-cell RNA-seq (scRNA-seq) and bulk RNA-seq data were performed to investigate the clonal evolution characteristics and to find novel prognostic targets in MM. The scRNA-seq data were analyzed by the Seurat pipeline and Monocle 2 to identify MM cell branches with different differentiation states. Marker genes in each branch were uploaded to the STRING database to...]]></summary>
        <author>
            <name>Jing Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations]]></title>
        <id>pubmed:36562835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36562835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolutionary dynamics allows us to understand many changes happening in a broad variety of biological systems, ranging from individuals to complete ecosystems. It is also behind a number of remarkable organizational changes that happen during the natural history of cancers. These reflect tumour heterogeneity, which is present at all cellular levels, including the genome, proteome and phenome, shaping its development and interrelation with its environment. An intriguing observation in different...]]></summary>
        <author>
            <name>Carmen Ortega-Sabater</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases]]></title>
        <id>pubmed:36561283</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36561283/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study represents the most comprehensive genomic characterization of NSCLC-BM available to date, paving the way to functional studies aimed at assessing the potential of the identified pathogenic alterations as clinical biomarkers and targets.]]></summary>
        <author>
            <name>Marcin Nico</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detection of <em>BRCA1</em>, and <em>BRCA2</em> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting]]></title>
        <id>pubmed:36551924</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551924/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: There is a high level of concordance between tissue and blood for BRCA mutations. Testing cfDNA can provide reliable information on BRCA mutational status and is a viable alternative to solid tissue sequencing when unavailable. The development of a new BRCA mutation later in the disease course is a rare event.]]></summary>
        <author>
            <name>Taylor Ryan McFarland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component]]></title>
        <id>pubmed:36551729</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36551729/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[An improved understanding of relapse kinetics is required to optimize detection and treatment strategies for the post-transplant relapse of myeloid neoplasms. Therefore, we retrospectively analyzed data from 91 patients allografted for MDS (n = 54), AML-MRC (n = 29) and chronic myelomonocytic leukemia (CMML, n = 8), who relapsed after transplant. Patients with early (<12 months, n = 56) and late relapse (>12 months, n = 35) were compared regarding patient-, disease- and transplant-related...]]></summary>
        <author>
            <name>Victoria Platte</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1(HTLV-1)-infected cells that display polylobulation. Here, we demonstrated...]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1(HTLV-1)-infected cells that display polylobulation. Here, we demonstrated...]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1(HTLV-1)-infected cells that display polylobulation. Here, we demonstrated...]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1(HTLV-1)-infected cells that display polylobulation. Here, we demonstrated...]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1(HTLV-1)-infected cells that display polylobulation. Here, we demonstrated...]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1(HTLV-1)-infected cells that display polylobulation. Here, we demonstrated...]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1(HTLV-1)-infected cells that display polylobulation. Here, we demonstrated...]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1(HTLV-1)-infected cells that display polylobulation. Here, we demonstrated...]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1(HTLV-1)-infected cells that display polylobulation. Here, we demonstrated...]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1(HTLV-1)-infected cells that display polylobulation. Here, we demonstrated...]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1(HTLV-1)-infected cells that display polylobulation. Here, we demonstrated...]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1(HTLV-1)-infected cells that display polylobulation. Here, we demonstrated...]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1(HTLV-1)-infected cells that display polylobulation. Here, we demonstrated...]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1(HTLV-1)-infected cells that display polylobulation. Here, we demonstrated...]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1(HTLV-1)-infected cells that display polylobulation. Here, we demonstrated...]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma]]></title>
        <id>pubmed:36541483</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36541483/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Makoto Nakashima</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA-testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA-testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA-testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA-testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA-testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA-testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA-testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA-testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA-testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA-testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA-testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA-testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA-testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA-testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue-independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA-testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells]]></title>
        <id>pubmed:36534496</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36534496/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Iris van 't Erve</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These results argue that genetic and immune heterogeneity jointly co-evolve and influence response to ICI in ccRCC. Our findings have implications for future biomarker development for ICI response across ccRCC and other solid tumors and highlight important features of tumor evolution under ICI treatment.]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nodal mature T-cell lymphomas (nMTCL) comprises a heterogeneous group of rare malignancies with aggressive biological behavior and poor prognosis. Epigenetic phenomena, including mutations in genes that control DNA methylation and histone deacetylation, in addition to inactivating mutations in the RhoA GTPase, play a central role in its pathogenesis and constitute potential new targets for therapeutic intervention. Tumor mutational burden (TMB) reflects the process of clonal evolution, predicts...]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutational signatures, the generic patterns of mutations, are the footprints of both endogenous and exogenous factors that have influenced cancer development. To date, dozens of mutational signatures have been discerned through computational methods. However, the etiology, mutational properties, clonality, immunology and prognostic value of mutation signatures across cancer types are poorly understood. To address this, we extensively characterized mutational signatures across 8,836 cancer...]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These results argue that genetic and immune heterogeneity jointly co-evolve and influence response to ICI in ccRCC. Our findings have implications for future biomarker development for ICI response across ccRCC and other solid tumors and highlight important features of tumor evolution under ICI treatment.]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nodal mature T-cell lymphomas (nMTCL) comprises a heterogeneous group of rare malignancies with aggressive biological behavior and poor prognosis. Epigenetic phenomena, including mutations in genes that control DNA methylation and histone deacetylation, in addition to inactivating mutations in the RhoA GTPase, play a central role in its pathogenesis and constitute potential new targets for therapeutic intervention. Tumor mutational burden (TMB) reflects the process of clonal evolution, predicts...]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutational signatures, the generic patterns of mutations, are the footprints of both endogenous and exogenous factors that have influenced cancer development. To date, dozens of mutational signatures have been discerned through computational methods. However, the etiology, mutational properties, clonality, immunology and prognostic value of mutation signatures across cancer types are poorly understood. To address this, we extensively characterized mutational signatures across 8,836 cancer...]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These results argue that genetic and immune heterogeneity jointly co-evolve and influence response to ICI in ccRCC. Our findings have implications for future biomarker development for ICI response across ccRCC and other solid tumors and highlight important features of tumor evolution under ICI treatment.]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nodal mature T-cell lymphomas (nMTCL) comprises a heterogeneous group of rare malignancies with aggressive biological behavior and poor prognosis. Epigenetic phenomena, including mutations in genes that control DNA methylation and histone deacetylation, in addition to inactivating mutations in the RhoA GTPase, play a central role in its pathogenesis and constitute potential new targets for therapeutic intervention. Tumor mutational burden (TMB) reflects the process of clonal evolution, predicts...]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutational signatures, the generic patterns of mutations, are the footprints of both endogenous and exogenous factors that have influenced cancer development. To date, dozens of mutational signatures have been discerned through computational methods. However, the etiology, mutational properties, clonality, immunology and prognostic value of mutation signatures across cancer types are poorly understood. To address this, we extensively characterized mutational signatures across 8,836 cancer...]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These results argue that genetic and immune heterogeneity jointly co-evolve and influence response to ICI in ccRCC. Our findings have implications for future biomarker development for ICI response across ccRCC and other solid tumors and highlight important features of tumor evolution under ICI treatment.]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nodal mature T-cell lymphomas (nMTCL) comprises a heterogeneous group of rare malignancies with aggressive biological behavior and poor prognosis. Epigenetic phenomena, including mutations in genes that control DNA methylation and histone deacetylation, in addition to inactivating mutations in the RhoA GTPase, play a central role in its pathogenesis and constitute potential new targets for therapeutic intervention. Tumor mutational burden (TMB) reflects the process of clonal evolution, predicts...]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutational signatures, the generic patterns of mutations, are the footprints of both endogenous and exogenous factors that have influenced cancer development. To date, dozens of mutational signatures have been discerned through computational methods. However, the etiology, mutational properties, clonality, immunology and prognostic value of mutation signatures across cancer types are poorly understood. To address this, we extensively characterized mutational signatures across 8,836 cancer...]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These results argue that genetic and immune heterogeneity jointly co-evolve and influence response to ICI in ccRCC. Our findings have implications for future biomarker development for ICI response across ccRCC and other solid tumors and highlight important features of tumor evolution under ICI treatment.]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nodal mature T-cell lymphomas (nMTCL) comprises a heterogeneous group of rare malignancies with aggressive biological behavior and poor prognosis. Epigenetic phenomena, including mutations in genes that control DNA methylation and histone deacetylation, in addition to inactivating mutations in the RhoA GTPase, play a central role in its pathogenesis and constitute potential new targets for therapeutic intervention. Tumor mutational burden (TMB) reflects the process of clonal evolution, predicts...]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutational signatures, the generic patterns of mutations, are the footprints of both endogenous and exogenous factors that have influenced cancer development. To date, dozens of mutational signatures have been discerned through computational methods. However, the etiology, mutational properties, clonality, immunology and prognostic value of mutation signatures across cancer types are poorly understood. To address this, we extensively characterized mutational signatures across 8,836 cancer...]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These results argue that genetic and immune heterogeneity jointly co-evolve and influence response to ICI in ccRCC. Our findings have implications for future biomarker development for ICI response across ccRCC and other solid tumors and highlight important features of tumor evolution under ICI treatment.]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nodal mature T-cell lymphomas (nMTCL) comprises a heterogeneous group of rare malignancies with aggressive biological behavior and poor prognosis. Epigenetic phenomena, including mutations in genes that control DNA methylation and histone deacetylation, in addition to inactivating mutations in the RhoA GTPase, play a central role in its pathogenesis and constitute potential new targets for therapeutic intervention. Tumor mutational burden (TMB) reflects the process of clonal evolution, predicts...]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutational signatures, the generic patterns of mutations, are the footprints of both endogenous and exogenous factors that have influenced cancer development. To date, dozens of mutational signatures have been discerned through computational methods. However, the etiology, mutational properties, clonality, immunology and prognostic value of mutation signatures across cancer types are poorly understood. To address this, we extensively characterized mutational signatures across 8,836 cancer...]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These results argue that genetic and immune heterogeneity jointly co-evolve and influence response to ICI in ccRCC. Our findings have implications for future biomarker development for ICI response across ccRCC and other solid tumors and highlight important features of tumor evolution under ICI treatment.]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nodal mature T-cell lymphomas (nMTCL) comprises a heterogeneous group of rare malignancies with aggressive biological behavior and poor prognosis. Epigenetic phenomena, including mutations in genes that control DNA methylation and histone deacetylation, in addition to inactivating mutations in the RhoA GTPase, play a central role in its pathogenesis and constitute potential new targets for therapeutic intervention. Tumor mutational burden (TMB) reflects the process of clonal evolution, predicts...]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutational signatures, the generic patterns of mutations, are the footprints of both endogenous and exogenous factors that have influenced cancer development. To date, dozens of mutational signatures have been discerned through computational methods. However, the etiology, mutational properties, clonality, immunology and prognostic value of mutation signatures across cancer types are poorly understood. To address this, we extensively characterized mutational signatures across 8,836 cancer...]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These results argue that genetic and immune heterogeneity jointly co-evolve and influence response to ICI in ccRCC. Our findings have implications for future biomarker development for ICI response across ccRCC and other solid tumors and highlight important features of tumor evolution under ICI treatment.]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nodal mature T-cell lymphomas (nMTCL) comprises a heterogeneous group of rare malignancies with aggressive biological behavior and poor prognosis. Epigenetic phenomena, including mutations in genes that control DNA methylation and histone deacetylation, in addition to inactivating mutations in the RhoA GTPase, play a central role in its pathogenesis and constitute potential new targets for therapeutic intervention. Tumor mutational burden (TMB) reflects the process of clonal evolution, predicts...]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutational signatures, the generic patterns of mutations, are the footprints of both endogenous and exogenous factors that have influenced cancer development. To date, dozens of mutational signatures have been discerned through computational methods. However, the etiology, mutational properties, clonality, immunology and prognostic value of mutation signatures across cancer types are poorly understood. To address this, we extensively characterized mutational signatures across 8,836 cancer...]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These results argue that genetic and immune heterogeneity jointly co-evolve and influence response to ICI in ccRCC. Our findings have implications for future biomarker development for ICI response across ccRCC and other solid tumors and highlight important features of tumor evolution under ICI treatment.]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nodal mature T-cell lymphomas (nMTCL) comprises a heterogeneous group of rare malignancies with aggressive biological behavior and poor prognosis. Epigenetic phenomena, including mutations in genes that control DNA methylation and histone deacetylation, in addition to inactivating mutations in the RhoA GTPase, play a central role in its pathogenesis and constitute potential new targets for therapeutic intervention. Tumor mutational burden (TMB) reflects the process of clonal evolution, predicts...]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutational signatures, the generic patterns of mutations, are the footprints of both endogenous and exogenous factors that have influenced cancer development. To date, dozens of mutational signatures have been discerned through computational methods. However, the etiology, mutational properties, clonality, immunology and prognostic value of mutation signatures across cancer types are poorly understood. To address this, we extensively characterized mutational signatures across 8,836 cancer...]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These results argue that genetic and immune heterogeneity jointly co-evolve and influence response to ICI in ccRCC. Our findings have implications for future biomarker development for ICI response across ccRCC and other solid tumors and highlight important features of tumor evolution under ICI treatment.]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nodal mature T-cell lymphomas (nMTCL) comprises a heterogeneous group of rare malignancies with aggressive biological behavior and poor prognosis. Epigenetic phenomena, including mutations in genes that control DNA methylation and histone deacetylation, in addition to inactivating mutations in the RhoA GTPase, play a central role in its pathogenesis and constitute potential new targets for therapeutic intervention. Tumor mutational burden (TMB) reflects the process of clonal evolution, predicts...]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutational signatures, the generic patterns of mutations, are the footprints of both endogenous and exogenous factors that have influenced cancer development. To date, dozens of mutational signatures have been discerned through computational methods. However, the etiology, mutational properties, clonality, immunology and prognostic value of mutation signatures across cancer types are poorly understood. To address this, we extensively characterized mutational signatures across 8,836 cancer...]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These results argue that genetic and immune heterogeneity jointly co-evolve and influence response to ICI in ccRCC. Our findings have implications for future biomarker development for ICI response across ccRCC and other solid tumors and highlight important features of tumor evolution under ICI treatment.]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nodal mature T-cell lymphomas (nMTCL) comprises a heterogeneous group of rare malignancies with aggressive biological behavior and poor prognosis. Epigenetic phenomena, including mutations in genes that control DNA methylation and histone deacetylation, in addition to inactivating mutations in the RhoA GTPase, play a central role in its pathogenesis and constitute potential new targets for therapeutic intervention. Tumor mutational burden (TMB) reflects the process of clonal evolution, predicts...]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutational signatures, the generic patterns of mutations, are the footprints of both endogenous and exogenous factors that have influenced cancer development. To date, dozens of mutational signatures have been discerned through computational methods. However, the etiology, mutational properties, clonality, immunology and prognostic value of mutation signatures across cancer types are poorly understood. To address this, we extensively characterized mutational signatures across 8,836 cancer...]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These results argue that genetic and immune heterogeneity jointly co-evolve and influence response to ICI in ccRCC. Our findings have implications for future biomarker development for ICI response across ccRCC and other solid tumors and highlight important features of tumor evolution under ICI treatment.]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nodal mature T-cell lymphomas (nMTCL) comprises a heterogeneous group of rare malignancies with aggressive biological behavior and poor prognosis. Epigenetic phenomena, including mutations in genes that control DNA methylation and histone deacetylation, in addition to inactivating mutations in the RhoA GTPase, play a central role in its pathogenesis and constitute potential new targets for therapeutic intervention. Tumor mutational burden (TMB) reflects the process of clonal evolution, predicts...]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutational signatures, the generic patterns of mutations, are the footprints of both endogenous and exogenous factors that have influenced cancer development. To date, dozens of mutational signatures have been discerned through computational methods. However, the etiology, mutational properties, clonality, immunology and prognostic value of mutation signatures across cancer types are poorly understood. To address this, we extensively characterized mutational signatures across 8,836 cancer...]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These results argue that genetic and immune heterogeneity jointly co-evolve and influence response to ICI in ccRCC. Our findings have implications for future biomarker development for ICI response across ccRCC and other solid tumors and highlight important features of tumor evolution under ICI treatment.]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nodal mature T-cell lymphomas (nMTCL) comprises a heterogeneous group of rare malignancies with aggressive biological behavior and poor prognosis. Epigenetic phenomena, including mutations in genes that control DNA methylation and histone deacetylation, in addition to inactivating mutations in the RhoA GTPase, play a central role in its pathogenesis and constitute potential new targets for therapeutic intervention. Tumor mutational burden (TMB) reflects the process of clonal evolution, predicts...]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutational signatures, the generic patterns of mutations, are the footprints of both endogenous and exogenous factors that have influenced cancer development. To date, dozens of mutational signatures have been discerned through computational methods. However, the etiology, mutational properties, clonality, immunology and prognostic value of mutation signatures across cancer types are poorly understood. To address this, we extensively characterized mutational signatures across 8,836 cancer...]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: These results argue that genetic and immune heterogeneity jointly co-evolve and influence response to ICI in ccRCC. Our findings have implications for future biomarker development for ICI response across ccRCC and other solid tumors and highlight important features of tumor evolution under ICI treatment.]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nodal mature T-cell lymphomas (nMTCL) comprises a heterogeneous group of rare malignancies with aggressive biological behavior and poor prognosis. Epigenetic phenomena, including mutations in genes that control DNA methylation and histone deacetylation, in addition to inactivating mutations in the RhoA GTPase, play a central role in its pathogenesis and constitute potential new targets for therapeutic intervention. Tumor mutational burden (TMB) reflects the process of clonal evolution, predicts...]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutational signatures, the generic patterns of mutations, are the footprints of both endogenous and exogenous factors that have influenced cancer development. To date, dozens of mutational signatures have been discerned through computational methods. However, the etiology, mutational properties, clonality, immunology and prognostic value of mutation signatures across cancer types are poorly understood. To address this, we extensively characterized mutational signatures across 8,836 cancer...]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape]]></title>
        <id>pubmed:36536472</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536472/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mahdi Golkaram</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas]]></title>
        <id>pubmed:36536430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36536430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Lus Alberto de Pdua Covas Lage</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and genomic characterization of mutational signatures across human cancers]]></title>
        <id>pubmed:36533638</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36533638/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jianlong Liao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to...]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to...]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to...]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to...]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to...]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to...]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to...]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to...]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to...]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to...]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to...]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to...]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to...]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to...]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to...]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors]]></title>
        <id>pubmed:36526735</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36526735/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Theodore P Braun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR-ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored...]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR-ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored...]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR-ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored...]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR-ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored...]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR-ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored...]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR-ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored...]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR-ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored...]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR-ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored...]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR-ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored...]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR-ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored...]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR-ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored...]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR-ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored...]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221216195636&amp;v=2.17.9"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>BCR-ABL1</em> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia]]></title>
        <id>pubmed:36518237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36518237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yanqing Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients...]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients...]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients...]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients...]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients...]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients...]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients...]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients...]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients...]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients...]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients...]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients...]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients...]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients...]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is common both in healthy individuals and patients with hematological cancers. Recent studies have showed worse prognosis for patients with multiple myeloma (MM) and non-Hodgkin lymphoma undergoing stem cell transplant, that have concomitant presence of CHIP. Data regarding the clinical and biological role of CHIP in plasma cell dyscrasias (PCDs) is rapidly increasing. However, the prevalence and prognostic implication of CHIP in patients...]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221216195635&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias]]></title>
        <id>pubmed:36503855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Stefano Testa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest that Neanderthal introgression provides opportunity for somatic mutations to accumulate, and that some Neanderthal introgression may impact liver cancer risk.]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest that Neanderthal introgression provides opportunity for somatic mutations to accumulate, and that some Neanderthal introgression may impact liver cancer risk.]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest that Neanderthal introgression provides opportunity for somatic mutations to accumulate, and that some Neanderthal introgression may impact liver cancer risk.]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest that Neanderthal introgression provides opportunity for somatic mutations to accumulate, and that some Neanderthal introgression may impact liver cancer risk.]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest that Neanderthal introgression provides opportunity for somatic mutations to accumulate, and that some Neanderthal introgression may impact liver cancer risk.]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest that Neanderthal introgression provides opportunity for somatic mutations to accumulate, and that some Neanderthal introgression may impact liver cancer risk.]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest that Neanderthal introgression provides opportunity for somatic mutations to accumulate, and that some Neanderthal introgression may impact liver cancer risk.]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest that Neanderthal introgression provides opportunity for somatic mutations to accumulate, and that some Neanderthal introgression may impact liver cancer risk.]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest that Neanderthal introgression provides opportunity for somatic mutations to accumulate, and that some Neanderthal introgression may impact liver cancer risk.]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our results suggest that Neanderthal introgression provides opportunity for somatic mutations to accumulate, and that some Neanderthal introgression may impact liver cancer risk.]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221216195636&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The role of Neanderthal introgression in liver cancer]]></title>
        <id>pubmed:36503519</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36503519/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Angela M Taravella Oill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are clonal disorders originated by the serial acquisition of somatic mutations in hematopoietic stem/progenitor cells. The major clinical entities are represented by polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), that are caused by driver mutations affecting JAK2, MPL or CALR. Disease progression is related to molecular and clonal evolution. PV and ET can progress to secondary myelofibrosis (sMF) but can also evolve to...]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are clonal disorders originated by the serial acquisition of somatic mutations in hematopoietic stem/progenitor cells. The major clinical entities are represented by polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), that are caused by driver mutations affecting JAK2, MPL or CALR. Disease progression is related to molecular and clonal evolution. PV and ET can progress to secondary myelofibrosis (sMF) but can also evolve to...]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The expression of gametogenesis-related (GG) genes and proteins, as well as whole genome duplications (WGD), are the hallmarks of cancer related to poor prognosis. Currently, it is not clear if these hallmarks are random processes associated only with genome instability or are programmatically linked. Our goal was to elucidate this via a thorough bioinformatics analysis of 1474 GG genes in the context of WGD. We examined their association in protein-protein interaction and coexpression networks,...]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are clonal disorders originated by the serial acquisition of somatic mutations in hematopoietic stem/progenitor cells. The major clinical entities are represented by polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), that are caused by driver mutations affecting JAK2, MPL or CALR. Disease progression is related to molecular and clonal evolution. PV and ET can progress to secondary myelofibrosis (sMF) but can also evolve to...]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The expression of gametogenesis-related (GG) genes and proteins, as well as whole genome duplications (WGD), are the hallmarks of cancer related to poor prognosis. Currently, it is not clear if these hallmarks are random processes associated only with genome instability or are programmatically linked. Our goal was to elucidate this via a thorough bioinformatics analysis of 1474 GG genes in the context of WGD. We examined their association in protein-protein interaction and coexpression networks,...]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are clonal disorders originated by the serial acquisition of somatic mutations in hematopoietic stem/progenitor cells. The major clinical entities are represented by polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), that are caused by driver mutations affecting JAK2, MPL or CALR. Disease progression is related to molecular and clonal evolution. PV and ET can progress to secondary myelofibrosis (sMF) but can also evolve to...]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The expression of gametogenesis-related (GG) genes and proteins, as well as whole genome duplications (WGD), are the hallmarks of cancer related to poor prognosis. Currently, it is not clear if these hallmarks are random processes associated only with genome instability or are programmatically linked. Our goal was to elucidate this via a thorough bioinformatics analysis of 1474 GG genes in the context of WGD. We examined their association in protein-protein interaction and coexpression networks,...]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer metastasis is the lethal developmental step in cancer, responsible for the majority of cancer deaths. To metastasise, cancer cells must acquire the ability to disseminate systemically and to escape an activated immune response. Here, we endeavoured to investigate if metastatic dissemination reflects acquisition of genomic traits that are selected for. We acquired mutation and copy number data from 8332 tumours representing 19 cancer types acquired from The Cancer Genome Atlas and the...]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are clonal disorders originated by the serial acquisition of somatic mutations in hematopoietic stem/progenitor cells. The major clinical entities are represented by polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), that are caused by driver mutations affecting JAK2, MPL or CALR. Disease progression is related to molecular and clonal evolution. PV and ET can progress to secondary myelofibrosis (sMF) but can also evolve to...]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The expression of gametogenesis-related (GG) genes and proteins, as well as whole genome duplications (WGD), are the hallmarks of cancer related to poor prognosis. Currently, it is not clear if these hallmarks are random processes associated only with genome instability or are programmatically linked. Our goal was to elucidate this via a thorough bioinformatics analysis of 1474 GG genes in the context of WGD. We examined their association in protein-protein interaction and coexpression networks,...]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer metastasis is the lethal developmental step in cancer, responsible for the majority of cancer deaths. To metastasise, cancer cells must acquire the ability to disseminate systemically and to escape an activated immune response. Here, we endeavoured to investigate if metastatic dissemination reflects acquisition of genomic traits that are selected for. We acquired mutation and copy number data from 8332 tumours representing 19 cancer types acquired from The Cancer Genome Atlas and the...]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are clonal disorders originated by the serial acquisition of somatic mutations in hematopoietic stem/progenitor cells. The major clinical entities are represented by polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), that are caused by driver mutations affecting JAK2, MPL or CALR. Disease progression is related to molecular and clonal evolution. PV and ET can progress to secondary myelofibrosis (sMF) but can also evolve to...]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The expression of gametogenesis-related (GG) genes and proteins, as well as whole genome duplications (WGD), are the hallmarks of cancer related to poor prognosis. Currently, it is not clear if these hallmarks are random processes associated only with genome instability or are programmatically linked. Our goal was to elucidate this via a thorough bioinformatics analysis of 1474 GG genes in the context of WGD. We examined their association in protein-protein interaction and coexpression networks,...]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer metastasis is the lethal developmental step in cancer, responsible for the majority of cancer deaths. To metastasise, cancer cells must acquire the ability to disseminate systemically and to escape an activated immune response. Here, we endeavoured to investigate if metastatic dissemination reflects acquisition of genomic traits that are selected for. We acquired mutation and copy number data from 8332 tumours representing 19 cancer types acquired from The Cancer Genome Atlas and the...]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are clonal disorders originated by the serial acquisition of somatic mutations in hematopoietic stem/progenitor cells. The major clinical entities are represented by polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), that are caused by driver mutations affecting JAK2, MPL or CALR. Disease progression is related to molecular and clonal evolution. PV and ET can progress to secondary myelofibrosis (sMF) but can also evolve to...]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The expression of gametogenesis-related (GG) genes and proteins, as well as whole genome duplications (WGD), are the hallmarks of cancer related to poor prognosis. Currently, it is not clear if these hallmarks are random processes associated only with genome instability or are programmatically linked. Our goal was to elucidate this via a thorough bioinformatics analysis of 1474 GG genes in the context of WGD. We examined their association in protein-protein interaction and coexpression networks,...]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer metastasis is the lethal developmental step in cancer, responsible for the majority of cancer deaths. To metastasise, cancer cells must acquire the ability to disseminate systemically and to escape an activated immune response. Here, we endeavoured to investigate if metastatic dissemination reflects acquisition of genomic traits that are selected for. We acquired mutation and copy number data from 8332 tumours representing 19 cancer types acquired from The Cancer Genome Atlas and the...]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are clonal disorders originated by the serial acquisition of somatic mutations in hematopoietic stem/progenitor cells. The major clinical entities are represented by polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), that are caused by driver mutations affecting JAK2, MPL or CALR. Disease progression is related to molecular and clonal evolution. PV and ET can progress to secondary myelofibrosis (sMF) but can also evolve to...]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The expression of gametogenesis-related (GG) genes and proteins, as well as whole genome duplications (WGD), are the hallmarks of cancer related to poor prognosis. Currently, it is not clear if these hallmarks are random processes associated only with genome instability or are programmatically linked. Our goal was to elucidate this via a thorough bioinformatics analysis of 1474 GG genes in the context of WGD. We examined their association in protein-protein interaction and coexpression networks,...]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer metastasis is the lethal developmental step in cancer, responsible for the majority of cancer deaths. To metastasise, cancer cells must acquire the ability to disseminate systemically and to escape an activated immune response. Here, we endeavoured to investigate if metastatic dissemination reflects acquisition of genomic traits that are selected for. We acquired mutation and copy number data from 8332 tumours representing 19 cancer types acquired from The Cancer Genome Atlas and the...]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are clonal disorders originated by the serial acquisition of somatic mutations in hematopoietic stem/progenitor cells. The major clinical entities are represented by polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), that are caused by driver mutations affecting JAK2, MPL or CALR. Disease progression is related to molecular and clonal evolution. PV and ET can progress to secondary myelofibrosis (sMF) but can also evolve to...]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The expression of gametogenesis-related (GG) genes and proteins, as well as whole genome duplications (WGD), are the hallmarks of cancer related to poor prognosis. Currently, it is not clear if these hallmarks are random processes associated only with genome instability or are programmatically linked. Our goal was to elucidate this via a thorough bioinformatics analysis of 1474 GG genes in the context of WGD. We examined their association in protein-protein interaction and coexpression networks,...]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer metastasis is the lethal developmental step in cancer, responsible for the majority of cancer deaths. To metastasise, cancer cells must acquire the ability to disseminate systemically and to escape an activated immune response. Here, we endeavoured to investigate if metastatic dissemination reflects acquisition of genomic traits that are selected for. We acquired mutation and copy number data from 8332 tumours representing 19 cancer types acquired from The Cancer Genome Atlas and the...]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221216195636&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221216195636&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221216195636&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective]]></title>
        <id>pubmed:36499582</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499582/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sebastiano Rontauroli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction]]></title>
        <id>pubmed:36499258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36499258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ninel M Vainshelbaum</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational Analysis Reveals the Temporal Acquisition of Pathway Alterations during the Evolution of Cancer]]></title>
        <id>pubmed:36497297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36497297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Johanne Ahrenfeldt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple...]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic cell transplantation, gene therapy, and gene editing offer a potential cure for sickle cell disease (SCD). Unfortunately, myelodysplastic syndrome and acute myeloid leukemia development have been higher than expected after graft rejection following nonmyeloablative conditioning and lentivirus-based gene therapy employing myeloablative busulfan for SCD. Somatic mutations discovered in 2 of 76 patients who rejected their grafts were identified at baseline at much lower...]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell disorders characterized by ineffective growth and differentiation of hematopoietic progenitors leading to peripheral blood cytopenias, dysplasia, and a variable risk of transformation to acute myelogenous leukemia. As most patients present with lower-risk disease, understanding the pathogenesis of ineffective hematopoiesis is important for developing therapies that will increase blood counts in...]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple...]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic cell transplantation, gene therapy, and gene editing offer a potential cure for sickle cell disease (SCD). Unfortunately, myelodysplastic syndrome and acute myeloid leukemia development have been higher than expected after graft rejection following nonmyeloablative conditioning and lentivirus-based gene therapy employing myeloablative busulfan for SCD. Somatic mutations discovered in 2 of 76 patients who rejected their grafts were identified at baseline at much lower...]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell disorders characterized by ineffective growth and differentiation of hematopoietic progenitors leading to peripheral blood cytopenias, dysplasia, and a variable risk of transformation to acute myelogenous leukemia. As most patients present with lower-risk disease, understanding the pathogenesis of ineffective hematopoiesis is important for developing therapies that will increase blood counts in...]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple...]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic cell transplantation, gene therapy, and gene editing offer a potential cure for sickle cell disease (SCD). Unfortunately, myelodysplastic syndrome and acute myeloid leukemia development have been higher than expected after graft rejection following nonmyeloablative conditioning and lentivirus-based gene therapy employing myeloablative busulfan for SCD. Somatic mutations discovered in 2 of 76 patients who rejected their grafts were identified at baseline at much lower...]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell disorders characterized by ineffective growth and differentiation of hematopoietic progenitors leading to peripheral blood cytopenias, dysplasia, and a variable risk of transformation to acute myelogenous leukemia. As most patients present with lower-risk disease, understanding the pathogenesis of ineffective hematopoiesis is important for developing therapies that will increase blood counts in...]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple...]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic cell transplantation, gene therapy, and gene editing offer a potential cure for sickle cell disease (SCD). Unfortunately, myelodysplastic syndrome and acute myeloid leukemia development have been higher than expected after graft rejection following nonmyeloablative conditioning and lentivirus-based gene therapy employing myeloablative busulfan for SCD. Somatic mutations discovered in 2 of 76 patients who rejected their grafts were identified at baseline at much lower...]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell disorders characterized by ineffective growth and differentiation of hematopoietic progenitors leading to peripheral blood cytopenias, dysplasia, and a variable risk of transformation to acute myelogenous leukemia. As most patients present with lower-risk disease, understanding the pathogenesis of ineffective hematopoiesis is important for developing therapies that will increase blood counts in...]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple...]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic cell transplantation, gene therapy, and gene editing offer a potential cure for sickle cell disease (SCD). Unfortunately, myelodysplastic syndrome and acute myeloid leukemia development have been higher than expected after graft rejection following nonmyeloablative conditioning and lentivirus-based gene therapy employing myeloablative busulfan for SCD. Somatic mutations discovered in 2 of 76 patients who rejected their grafts were identified at baseline at much lower...]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell disorders characterized by ineffective growth and differentiation of hematopoietic progenitors leading to peripheral blood cytopenias, dysplasia, and a variable risk of transformation to acute myelogenous leukemia. As most patients present with lower-risk disease, understanding the pathogenesis of ineffective hematopoiesis is important for developing therapies that will increase blood counts in...]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple...]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic cell transplantation, gene therapy, and gene editing offer a potential cure for sickle cell disease (SCD). Unfortunately, myelodysplastic syndrome and acute myeloid leukemia development have been higher than expected after graft rejection following nonmyeloablative conditioning and lentivirus-based gene therapy employing myeloablative busulfan for SCD. Somatic mutations discovered in 2 of 76 patients who rejected their grafts were identified at baseline at much lower...]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell disorders characterized by ineffective growth and differentiation of hematopoietic progenitors leading to peripheral blood cytopenias, dysplasia, and a variable risk of transformation to acute myelogenous leukemia. As most patients present with lower-risk disease, understanding the pathogenesis of ineffective hematopoiesis is important for developing therapies that will increase blood counts in...]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple...]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic cell transplantation, gene therapy, and gene editing offer a potential cure for sickle cell disease (SCD). Unfortunately, myelodysplastic syndrome and acute myeloid leukemia development have been higher than expected after graft rejection following nonmyeloablative conditioning and lentivirus-based gene therapy employing myeloablative busulfan for SCD. Somatic mutations discovered in 2 of 76 patients who rejected their grafts were identified at baseline at much lower...]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell disorders characterized by ineffective growth and differentiation of hematopoietic progenitors leading to peripheral blood cytopenias, dysplasia, and a variable risk of transformation to acute myelogenous leukemia. As most patients present with lower-risk disease, understanding the pathogenesis of ineffective hematopoiesis is important for developing therapies that will increase blood counts in...]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple...]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic cell transplantation, gene therapy, and gene editing offer a potential cure for sickle cell disease (SCD). Unfortunately, myelodysplastic syndrome and acute myeloid leukemia development have been higher than expected after graft rejection following nonmyeloablative conditioning and lentivirus-based gene therapy employing myeloablative busulfan for SCD. Somatic mutations discovered in 2 of 76 patients who rejected their grafts were identified at baseline at much lower...]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell disorders characterized by ineffective growth and differentiation of hematopoietic progenitors leading to peripheral blood cytopenias, dysplasia, and a variable risk of transformation to acute myelogenous leukemia. As most patients present with lower-risk disease, understanding the pathogenesis of ineffective hematopoiesis is important for developing therapies that will increase blood counts in...]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple...]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic cell transplantation, gene therapy, and gene editing offer a potential cure for sickle cell disease (SCD). Unfortunately, myelodysplastic syndrome and acute myeloid leukemia development have been higher than expected after graft rejection following nonmyeloablative conditioning and lentivirus-based gene therapy employing myeloablative busulfan for SCD. Somatic mutations discovered in 2 of 76 patients who rejected their grafts were identified at baseline at much lower...]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell disorders characterized by ineffective growth and differentiation of hematopoietic progenitors leading to peripheral blood cytopenias, dysplasia, and a variable risk of transformation to acute myelogenous leukemia. As most patients present with lower-risk disease, understanding the pathogenesis of ineffective hematopoiesis is important for developing therapies that will increase blood counts in...]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple...]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic cell transplantation, gene therapy, and gene editing offer a potential cure for sickle cell disease (SCD). Unfortunately, myelodysplastic syndrome and acute myeloid leukemia development have been higher than expected after graft rejection following nonmyeloablative conditioning and lentivirus-based gene therapy employing myeloablative busulfan for SCD. Somatic mutations discovered in 2 of 76 patients who rejected their grafts were identified at baseline at much lower...]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell disorders characterized by ineffective growth and differentiation of hematopoietic progenitors leading to peripheral blood cytopenias, dysplasia, and a variable risk of transformation to acute myelogenous leukemia. As most patients present with lower-risk disease, understanding the pathogenesis of ineffective hematopoiesis is important for developing therapies that will increase blood counts in...]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple...]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic cell transplantation, gene therapy, and gene editing offer a potential cure for sickle cell disease (SCD). Unfortunately, myelodysplastic syndrome and acute myeloid leukemia development have been higher than expected after graft rejection following nonmyeloablative conditioning and lentivirus-based gene therapy employing myeloablative busulfan for SCD. Somatic mutations discovered in 2 of 76 patients who rejected their grafts were identified at baseline at much lower...]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell disorders characterized by ineffective growth and differentiation of hematopoietic progenitors leading to peripheral blood cytopenias, dysplasia, and a variable risk of transformation to acute myelogenous leukemia. As most patients present with lower-risk disease, understanding the pathogenesis of ineffective hematopoiesis is important for developing therapies that will increase blood counts in...]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple...]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic cell transplantation, gene therapy, and gene editing offer a potential cure for sickle cell disease (SCD). Unfortunately, myelodysplastic syndrome and acute myeloid leukemia development have been higher than expected after graft rejection following nonmyeloablative conditioning and lentivirus-based gene therapy employing myeloablative busulfan for SCD. Somatic mutations discovered in 2 of 76 patients who rejected their grafts were identified at baseline at much lower...]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell disorders characterized by ineffective growth and differentiation of hematopoietic progenitors leading to peripheral blood cytopenias, dysplasia, and a variable risk of transformation to acute myelogenous leukemia. As most patients present with lower-risk disease, understanding the pathogenesis of ineffective hematopoiesis is important for developing therapies that will increase blood counts in...]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple...]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic cell transplantation, gene therapy, and gene editing offer a potential cure for sickle cell disease (SCD). Unfortunately, myelodysplastic syndrome and acute myeloid leukemia development have been higher than expected after graft rejection following nonmyeloablative conditioning and lentivirus-based gene therapy employing myeloablative busulfan for SCD. Somatic mutations discovered in 2 of 76 patients who rejected their grafts were identified at baseline at much lower...]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell disorders characterized by ineffective growth and differentiation of hematopoietic progenitors leading to peripheral blood cytopenias, dysplasia, and a variable risk of transformation to acute myelogenous leukemia. As most patients present with lower-risk disease, understanding the pathogenesis of ineffective hematopoiesis is important for developing therapies that will increase blood counts in...]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple...]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic cell transplantation, gene therapy, and gene editing offer a potential cure for sickle cell disease (SCD). Unfortunately, myelodysplastic syndrome and acute myeloid leukemia development have been higher than expected after graft rejection following nonmyeloablative conditioning and lentivirus-based gene therapy employing myeloablative busulfan for SCD. Somatic mutations discovered in 2 of 76 patients who rejected their grafts were identified at baseline at much lower...]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell disorders characterized by ineffective growth and differentiation of hematopoietic progenitors leading to peripheral blood cytopenias, dysplasia, and a variable risk of transformation to acute myelogenous leukemia. As most patients present with lower-risk disease, understanding the pathogenesis of ineffective hematopoiesis is important for developing therapies that will increase blood counts in...]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple...]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic cell transplantation, gene therapy, and gene editing offer a potential cure for sickle cell disease (SCD). Unfortunately, myelodysplastic syndrome and acute myeloid leukemia development have been higher than expected after graft rejection following nonmyeloablative conditioning and lentivirus-based gene therapy employing myeloablative busulfan for SCD. Somatic mutations discovered in 2 of 76 patients who rejected their grafts were identified at baseline at much lower...]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The myelodysplastic syndromes (MDS) are a heterogeneous group of malignant hematopoietic stem cell disorders characterized by ineffective growth and differentiation of hematopoietic progenitors leading to peripheral blood cytopenias, dysplasia, and a variable risk of transformation to acute myelogenous leukemia. As most patients present with lower-risk disease, understanding the pathogenesis of ineffective hematopoiesis is important for developing therapies that will increase blood counts in...]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221216195635&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221216195635&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221216195635&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy]]></title>
        <id>pubmed:36493342</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36493342/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Annatina Sarah Schnegg-Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease]]></title>
        <id>pubmed:36485129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Courtney D Fitzhugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeting inflammation in lower-risk MDS]]></title>
        <id>pubmed:36485128</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485128/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Jesus D Gonzalez-Lugo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by morphologic dysplasia, persistent cytopenia, and a variable risk of evolution to acute myeloid leukemia (AML). Risk stratification is crucial in a patient-centered approach to the treatment of MDS. Based on hematologic parameters and cytogenetic abnormalities, the Revised International Prognostic Scoring System is currently used for this purpose. In the past years, the use of massively parallel DNA sequencing has clarified...]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modern management of Fanconi anemia]]></title>
        <id>pubmed:36485157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this review, we present a clinical case report and discussion to outline the importance of long-term specific Fanconi anemia (FA) monitoring, and we discuss the main aspects of the general management of patients with FA and clinical complications. While several nontransplant treatments are currently under evaluation, hematopoietic stem cell transplantation (HSCT) remains the only therapeutic option for bone marrow failure (BMF). Although HSCT outcomes in patients with FA have remarkably...]]></summary>
        <author>
            <name>Carlo Dufour</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by morphologic dysplasia, persistent cytopenia, and a variable risk of evolution to acute myeloid leukemia (AML). Risk stratification is crucial in a patient-centered approach to the treatment of MDS. Based on hematologic parameters and cytogenetic abnormalities, the Revised International Prognostic Scoring System is currently used for this purpose. In the past years, the use of massively parallel DNA sequencing has clarified...]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modern management of Fanconi anemia]]></title>
        <id>pubmed:36485157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this review, we present a clinical case report and discussion to outline the importance of long-term specific Fanconi anemia (FA) monitoring, and we discuss the main aspects of the general management of patients with FA and clinical complications. While several nontransplant treatments are currently under evaluation, hematopoietic stem cell transplantation (HSCT) remains the only therapeutic option for bone marrow failure (BMF). Although HSCT outcomes in patients with FA have remarkably...]]></summary>
        <author>
            <name>Carlo Dufour</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by morphologic dysplasia, persistent cytopenia, and a variable risk of evolution to acute myeloid leukemia (AML). Risk stratification is crucial in a patient-centered approach to the treatment of MDS. Based on hematologic parameters and cytogenetic abnormalities, the Revised International Prognostic Scoring System is currently used for this purpose. In the past years, the use of massively parallel DNA sequencing has clarified...]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modern management of Fanconi anemia]]></title>
        <id>pubmed:36485157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this review, we present a clinical case report and discussion to outline the importance of long-term specific Fanconi anemia (FA) monitoring, and we discuss the main aspects of the general management of patients with FA and clinical complications. While several nontransplant treatments are currently under evaluation, hematopoietic stem cell transplantation (HSCT) remains the only therapeutic option for bone marrow failure (BMF). Although HSCT outcomes in patients with FA have remarkably...]]></summary>
        <author>
            <name>Carlo Dufour</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modern management of Fanconi anemia]]></title>
        <id>pubmed:36485157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Carlo Dufour</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modern management of Fanconi anemia]]></title>
        <id>pubmed:36485157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Carlo Dufour</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modern management of Fanconi anemia]]></title>
        <id>pubmed:36485157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Carlo Dufour</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modern management of Fanconi anemia]]></title>
        <id>pubmed:36485157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Carlo Dufour</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modern management of Fanconi anemia]]></title>
        <id>pubmed:36485157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Carlo Dufour</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modern management of Fanconi anemia]]></title>
        <id>pubmed:36485157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Carlo Dufour</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221216195636&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modern management of Fanconi anemia]]></title>
        <id>pubmed:36485157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221216195636&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Carlo Dufour</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modern management of Fanconi anemia]]></title>
        <id>pubmed:36485157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Carlo Dufour</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modern management of Fanconi anemia]]></title>
        <id>pubmed:36485157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Carlo Dufour</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modern management of Fanconi anemia]]></title>
        <id>pubmed:36485157</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485157/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Carlo Dufour</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk stratifying MDS in the time of precision medicine]]></title>
        <id>pubmed:36485160</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36485160/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Mario Cazzola</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230106200039&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230105200111&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell (HSC) maintenance in vitro is challenging because stem cell survival relies on cell-to-cell contacts and paracrine signals from bone marrow (BM) microenvironment. Indeed, HSCs easily differentiate in conventional culture systems, and in vitro study of stem cell biology, leukemogenesis, and evolutionary trajectories is limited. 3D-culture systems can mimic tissue architecture and microenvironment thus preserving HSC phenotype. In this study, we developed a calcium alginate...]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell (HSC) maintenance in vitro is challenging because stem cell survival relies on cell-to-cell contacts and paracrine signals from bone marrow (BM) microenvironment. Indeed, HSCs easily differentiate in conventional culture systems, and in vitro study of stem cell biology, leukemogenesis, and evolutionary trajectories is limited. 3D-culture systems can mimic tissue architecture and microenvironment thus preserving HSC phenotype. In this study, we developed a calcium alginate...]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell (HSC) maintenance in vitro is challenging because stem cell survival relies on cell-to-cell contacts and paracrine signals from bone marrow (BM) microenvironment. Indeed, HSCs easily differentiate in conventional culture systems, and in vitro study of stem cell biology, leukemogenesis, and evolutionary trajectories is limited. 3D-culture systems can mimic tissue architecture and microenvironment thus preserving HSC phenotype. In this study, we developed a calcium alginate...]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell (HSC) maintenance in vitro is challenging because stem cell survival relies on cell-to-cell contacts and paracrine signals from bone marrow (BM) microenvironment. Indeed, HSCs easily differentiate in conventional culture systems, and in vitro study of stem cell biology, leukemogenesis, and evolutionary trajectories is limited. 3D-culture systems can mimic tissue architecture and microenvironment thus preserving HSC phenotype. In this study, we developed a calcium alginate...]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell (HSC) maintenance in vitro is challenging because stem cell survival relies on cell-to-cell contacts and paracrine signals from bone marrow (BM) microenvironment. Indeed, HSCs easily differentiate in conventional culture systems, and in vitro study of stem cell biology, leukemogenesis, and evolutionary trajectories is limited. 3D-culture systems can mimic tissue architecture and microenvironment thus preserving HSC phenotype. In this study, we developed a calcium alginate...]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell (HSC) maintenance in vitro is challenging because stem cell survival relies on cell-to-cell contacts and paracrine signals from bone marrow (BM) microenvironment. Indeed, HSCs easily differentiate in conventional culture systems, and in vitro study of stem cell biology, leukemogenesis, and evolutionary trajectories is limited. 3D-culture systems can mimic tissue architecture and microenvironment thus preserving HSC phenotype. In this study, we developed a calcium alginate...]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell (HSC) maintenance in vitro is challenging because stem cell survival relies on cell-to-cell contacts and paracrine signals from bone marrow (BM) microenvironment. Indeed, HSCs easily differentiate in conventional culture systems, and in vitro study of stem cell biology, leukemogenesis, and evolutionary trajectories is limited. 3D-culture systems can mimic tissue architecture and microenvironment thus preserving HSC phenotype. In this study, we developed a calcium alginate...]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell (HSC) maintenance in vitro is challenging because stem cell survival relies on cell-to-cell contacts and paracrine signals from bone marrow (BM) microenvironment. Indeed, HSCs easily differentiate in conventional culture systems, and in vitro study of stem cell biology, leukemogenesis, and evolutionary trajectories is limited. 3D-culture systems can mimic tissue architecture and microenvironment thus preserving HSC phenotype. In this study, we developed a calcium alginate...]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell (HSC) maintenance in vitro is challenging because stem cell survival relies on cell-to-cell contacts and paracrine signals from bone marrow (BM) microenvironment. Indeed, HSCs easily differentiate in conventional culture systems, and in vitro study of stem cell biology, leukemogenesis, and evolutionary trajectories is limited. 3D-culture systems can mimic tissue architecture and microenvironment thus preserving HSC phenotype. In this study, we developed a calcium alginate...]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell (HSC) maintenance in vitro is challenging because stem cell survival relies on cell-to-cell contacts and paracrine signals from bone marrow (BM) microenvironment. Indeed, HSCs easily differentiate in conventional culture systems, and in vitro study of stem cell biology, leukemogenesis, and evolutionary trajectories is limited. 3D-culture systems can mimic tissue architecture and microenvironment thus preserving HSC phenotype. In this study, we developed a calcium alginate...]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell (HSC) maintenance in vitro is challenging because stem cell survival relies on cell-to-cell contacts and paracrine signals from bone marrow (BM) microenvironment. Indeed, HSCs easily differentiate in conventional culture systems, and in vitro study of stem cell biology, leukemogenesis, and evolutionary trajectories is limited. 3D-culture systems can mimic tissue architecture and microenvironment thus preserving HSC phenotype. In this study, we developed a calcium alginate...]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell (HSC) maintenance in vitro is challenging because stem cell survival relies on cell-to-cell contacts and paracrine signals from bone marrow (BM) microenvironment. Indeed, HSCs easily differentiate in conventional culture systems, and in vitro study of stem cell biology, leukemogenesis, and evolutionary trajectories is limited. 3D-culture systems can mimic tissue architecture and microenvironment thus preserving HSC phenotype. In this study, we developed a calcium alginate...]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cell (HSC) maintenance in vitro is challenging because stem cell survival relies on cell-to-cell contacts and paracrine signals from bone marrow (BM) microenvironment. Indeed, HSCs easily differentiate in conventional culture systems, and in vitro study of stem cell biology, leukemogenesis, and evolutionary trajectories is limited. 3D-culture systems can mimic tissue architecture and microenvironment thus preserving HSC phenotype. In this study, we developed a calcium alginate...]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221216195635&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221216195635&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Risk of Incident Lung Cancer]]></title>
        <id>pubmed:36480766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ruiyi Tian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche]]></title>
        <id>pubmed:36478848</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36478848/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Paola Manzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer]]></title>
        <id>pubmed:36480186</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480186/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Weisi Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic landscape of chronic myeloid leukemia]]></title>
        <id>pubmed:36477676</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477676/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology]]></title>
        <id>pubmed:36477267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ankit K Dutta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors]]></title>
        <id>pubmed:36476508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36476508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Minsu Kang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer]]></title>
        <id>pubmed:36480186</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480186/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Weisi Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic landscape of chronic myeloid leukemia]]></title>
        <id>pubmed:36477676</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477676/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology]]></title>
        <id>pubmed:36477267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ankit K Dutta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors]]></title>
        <id>pubmed:36476508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36476508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Minsu Kang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer]]></title>
        <id>pubmed:36480186</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480186/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Weisi Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic landscape of chronic myeloid leukemia]]></title>
        <id>pubmed:36477676</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477676/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology]]></title>
        <id>pubmed:36477267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ankit K Dutta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors]]></title>
        <id>pubmed:36476508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36476508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Minsu Kang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Testing for Phylogenetic Signal in Single-Cell RNA-Seq Data]]></title>
        <id>pubmed:36475926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36475926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ji C Moravec</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer]]></title>
        <id>pubmed:36480186</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480186/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Weisi Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic landscape of chronic myeloid leukemia]]></title>
        <id>pubmed:36477676</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477676/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology]]></title>
        <id>pubmed:36477267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ankit K Dutta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors]]></title>
        <id>pubmed:36476508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36476508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Minsu Kang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Testing for Phylogenetic Signal in Single-Cell RNA-Seq Data]]></title>
        <id>pubmed:36475926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36475926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ji C Moravec</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer]]></title>
        <id>pubmed:36480186</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480186/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Weisi Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic landscape of chronic myeloid leukemia]]></title>
        <id>pubmed:36477676</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477676/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology]]></title>
        <id>pubmed:36477267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ankit K Dutta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors]]></title>
        <id>pubmed:36476508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36476508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Minsu Kang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Testing for Phylogenetic Signal in Single-Cell RNA-Seq Data]]></title>
        <id>pubmed:36475926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36475926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ji C Moravec</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer]]></title>
        <id>pubmed:36480186</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480186/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Weisi Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic landscape of chronic myeloid leukemia]]></title>
        <id>pubmed:36477676</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477676/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology]]></title>
        <id>pubmed:36477267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ankit K Dutta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors]]></title>
        <id>pubmed:36476508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36476508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Minsu Kang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Testing for Phylogenetic Signal in Single-Cell RNA-Seq Data]]></title>
        <id>pubmed:36475926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36475926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ji C Moravec</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer]]></title>
        <id>pubmed:36480186</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480186/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221216195636&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Weisi Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic landscape of chronic myeloid leukemia]]></title>
        <id>pubmed:36477676</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477676/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221216195636&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology]]></title>
        <id>pubmed:36477267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221216195636&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ankit K Dutta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors]]></title>
        <id>pubmed:36476508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36476508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221216195636&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Minsu Kang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Testing for Phylogenetic Signal in Single-Cell RNA-Seq Data]]></title>
        <id>pubmed:36475926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36475926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221216195636&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ji C Moravec</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer]]></title>
        <id>pubmed:36480186</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480186/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Weisi Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic landscape of chronic myeloid leukemia]]></title>
        <id>pubmed:36477676</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477676/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology]]></title>
        <id>pubmed:36477267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ankit K Dutta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors]]></title>
        <id>pubmed:36476508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36476508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Minsu Kang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Testing for Phylogenetic Signal in Single-Cell RNA-Seq Data]]></title>
        <id>pubmed:36475926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36475926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ji C Moravec</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer]]></title>
        <id>pubmed:36480186</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480186/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Weisi Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic landscape of chronic myeloid leukemia]]></title>
        <id>pubmed:36477676</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477676/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology]]></title>
        <id>pubmed:36477267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ankit K Dutta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors]]></title>
        <id>pubmed:36476508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36476508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Minsu Kang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Testing for Phylogenetic Signal in Single-Cell RNA-Seq Data]]></title>
        <id>pubmed:36475926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36475926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ji C Moravec</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer]]></title>
        <id>pubmed:36480186</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480186/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Weisi Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic landscape of chronic myeloid leukemia]]></title>
        <id>pubmed:36477676</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477676/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology]]></title>
        <id>pubmed:36477267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ankit K Dutta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors]]></title>
        <id>pubmed:36476508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36476508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Minsu Kang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Testing for Phylogenetic Signal in Single-Cell RNA-Seq Data]]></title>
        <id>pubmed:36475926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36475926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ji C Moravec</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer]]></title>
        <id>pubmed:36480186</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480186/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Weisi Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic landscape of chronic myeloid leukemia]]></title>
        <id>pubmed:36477676</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477676/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology]]></title>
        <id>pubmed:36477267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ankit K Dutta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors]]></title>
        <id>pubmed:36476508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36476508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Minsu Kang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Testing for Phylogenetic Signal in Single-Cell RNA-Seq Data]]></title>
        <id>pubmed:36475926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36475926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ji C Moravec</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer]]></title>
        <id>pubmed:36480186</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480186/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Weisi Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic landscape of chronic myeloid leukemia]]></title>
        <id>pubmed:36477676</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477676/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology]]></title>
        <id>pubmed:36477267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ankit K Dutta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors]]></title>
        <id>pubmed:36476508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36476508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Minsu Kang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Testing for Phylogenetic Signal in Single-Cell RNA-Seq Data]]></title>
        <id>pubmed:36475926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36475926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ji C Moravec</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer]]></title>
        <id>pubmed:36480186</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480186/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Weisi Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic landscape of chronic myeloid leukemia]]></title>
        <id>pubmed:36477676</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477676/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology]]></title>
        <id>pubmed:36477267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ankit K Dutta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors]]></title>
        <id>pubmed:36476508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36476508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Minsu Kang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Testing for Phylogenetic Signal in Single-Cell RNA-Seq Data]]></title>
        <id>pubmed:36475926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36475926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ji C Moravec</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer]]></title>
        <id>pubmed:36480186</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480186/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Weisi Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic landscape of chronic myeloid leukemia]]></title>
        <id>pubmed:36477676</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477676/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology]]></title>
        <id>pubmed:36477267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ankit K Dutta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors]]></title>
        <id>pubmed:36476508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36476508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Minsu Kang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Testing for Phylogenetic Signal in Single-Cell RNA-Seq Data]]></title>
        <id>pubmed:36475926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36475926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ji C Moravec</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer]]></title>
        <id>pubmed:36480186</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36480186/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Weisi Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic landscape of chronic myeloid leukemia]]></title>
        <id>pubmed:36477676</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477676/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology]]></title>
        <id>pubmed:36477267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36477267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ankit K Dutta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors]]></title>
        <id>pubmed:36476508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36476508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Minsu Kang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Testing for Phylogenetic Signal in Single-Cell RNA-Seq Data]]></title>
        <id>pubmed:36475926</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36475926/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ji C Moravec</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Echoed induction of nucleotide variants and chromosomal structural variants in cancer cells]]></title>
        <id>pubmed:36470958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yusuke Matsuno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer]]></title>
        <id>pubmed:36470901</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470901/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Smruthy Sivakumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Echoed induction of nucleotide variants and chromosomal structural variants in cancer cells]]></title>
        <id>pubmed:36470958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yusuke Matsuno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer]]></title>
        <id>pubmed:36470901</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470901/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Smruthy Sivakumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models]]></title>
        <id>pubmed:36469010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36469010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Livius Penter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Echoed induction of nucleotide variants and chromosomal structural variants in cancer cells]]></title>
        <id>pubmed:36470958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yusuke Matsuno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer]]></title>
        <id>pubmed:36470901</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470901/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Smruthy Sivakumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models]]></title>
        <id>pubmed:36469010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36469010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Livius Penter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Echoed induction of nucleotide variants and chromosomal structural variants in cancer cells]]></title>
        <id>pubmed:36470958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221216195636&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yusuke Matsuno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer]]></title>
        <id>pubmed:36470901</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470901/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221216195636&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Smruthy Sivakumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models]]></title>
        <id>pubmed:36469010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36469010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221216195636&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Livius Penter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Echoed induction of nucleotide variants and chromosomal structural variants in cancer cells]]></title>
        <id>pubmed:36470958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yusuke Matsuno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer]]></title>
        <id>pubmed:36470901</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470901/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Smruthy Sivakumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models]]></title>
        <id>pubmed:36469010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36469010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Livius Penter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Echoed induction of nucleotide variants and chromosomal structural variants in cancer cells]]></title>
        <id>pubmed:36470958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yusuke Matsuno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer]]></title>
        <id>pubmed:36470901</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470901/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Smruthy Sivakumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models]]></title>
        <id>pubmed:36469010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36469010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Livius Penter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current concepts of anti-EGFR targeting in metastatic colorectal cancer]]></title>
        <id>pubmed:36465407</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36465407/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Bernhard Doleschal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Echoed induction of nucleotide variants and chromosomal structural variants in cancer cells]]></title>
        <id>pubmed:36470958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yusuke Matsuno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer]]></title>
        <id>pubmed:36470901</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470901/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Smruthy Sivakumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models]]></title>
        <id>pubmed:36469010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36469010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Livius Penter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current concepts of anti-EGFR targeting in metastatic colorectal cancer]]></title>
        <id>pubmed:36465407</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36465407/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Bernhard Doleschal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Echoed induction of nucleotide variants and chromosomal structural variants in cancer cells]]></title>
        <id>pubmed:36470958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yusuke Matsuno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer]]></title>
        <id>pubmed:36470901</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470901/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Smruthy Sivakumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models]]></title>
        <id>pubmed:36469010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36469010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Livius Penter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current concepts of anti-EGFR targeting in metastatic colorectal cancer]]></title>
        <id>pubmed:36465407</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36465407/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Bernhard Doleschal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Echoed induction of nucleotide variants and chromosomal structural variants in cancer cells]]></title>
        <id>pubmed:36470958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yusuke Matsuno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer]]></title>
        <id>pubmed:36470901</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470901/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Smruthy Sivakumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models]]></title>
        <id>pubmed:36469010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36469010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Livius Penter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current concepts of anti-EGFR targeting in metastatic colorectal cancer]]></title>
        <id>pubmed:36465407</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36465407/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Bernhard Doleschal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Echoed induction of nucleotide variants and chromosomal structural variants in cancer cells]]></title>
        <id>pubmed:36470958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yusuke Matsuno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer]]></title>
        <id>pubmed:36470901</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470901/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Smruthy Sivakumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models]]></title>
        <id>pubmed:36469010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36469010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Livius Penter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current concepts of anti-EGFR targeting in metastatic colorectal cancer]]></title>
        <id>pubmed:36465407</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36465407/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Bernhard Doleschal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Echoed induction of nucleotide variants and chromosomal structural variants in cancer cells]]></title>
        <id>pubmed:36470958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yusuke Matsuno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer]]></title>
        <id>pubmed:36470901</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470901/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Smruthy Sivakumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models]]></title>
        <id>pubmed:36469010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36469010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Livius Penter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current concepts of anti-EGFR targeting in metastatic colorectal cancer]]></title>
        <id>pubmed:36465407</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36465407/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Bernhard Doleschal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Echoed induction of nucleotide variants and chromosomal structural variants in cancer cells]]></title>
        <id>pubmed:36470958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yusuke Matsuno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer]]></title>
        <id>pubmed:36470901</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470901/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Smruthy Sivakumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models]]></title>
        <id>pubmed:36469010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36469010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Livius Penter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current concepts of anti-EGFR targeting in metastatic colorectal cancer]]></title>
        <id>pubmed:36465407</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36465407/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Bernhard Doleschal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Echoed induction of nucleotide variants and chromosomal structural variants in cancer cells]]></title>
        <id>pubmed:36470958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yusuke Matsuno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer]]></title>
        <id>pubmed:36470901</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470901/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Smruthy Sivakumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models]]></title>
        <id>pubmed:36469010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36469010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Livius Penter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current concepts of anti-EGFR targeting in metastatic colorectal cancer]]></title>
        <id>pubmed:36465407</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36465407/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Bernhard Doleschal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer]]></title>
        <id>pubmed:36470901</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36470901/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Smruthy Sivakumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models]]></title>
        <id>pubmed:36469010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36469010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Livius Penter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current concepts of anti-EGFR targeting in metastatic colorectal cancer]]></title>
        <id>pubmed:36465407</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36465407/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Bernhard Doleschal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models]]></title>
        <id>pubmed:36469010</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36469010/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Livius Penter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Current concepts of anti-EGFR targeting in metastatic colorectal cancer]]></title>
        <id>pubmed:36465407</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36465407/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-12-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Bernhard Doleschal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230104200141&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[TNF receptor signaling distinctly promotes self-renewal and lymphoid differentiation in Dnmt3a-mutant hematopoietic stem cells, contributing to clonal hematopoiesis of indeterminate potential. See related article by SanMiguel et al., p. 2763 (3).]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230103195941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[TNF receptor signaling distinctly promotes self-renewal and lymphoid differentiation in Dnmt3a-mutant hematopoietic stem cells, contributing to clonal hematopoiesis of indeterminate potential. See related article by SanMiguel et al., p. 2763 (3).]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[TNF receptor signaling distinctly promotes self-renewal and lymphoid differentiation in Dnmt3a-mutant hematopoietic stem cells, contributing to clonal hematopoiesis of indeterminate potential. See related article by SanMiguel et al., p. 2763 (3).]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[TNF receptor signaling distinctly promotes self-renewal and lymphoid differentiation in Dnmt3a-mutant hematopoietic stem cells, contributing to clonal hematopoiesis of indeterminate potential. See related article by SanMiguel et al., p. 2763 (3).]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[TNF receptor signaling distinctly promotes self-renewal and lymphoid differentiation in Dnmt3a-mutant hematopoietic stem cells, contributing to clonal hematopoiesis of indeterminate potential. See related article by SanMiguel et al., p. 2763 (3).]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[TNF receptor signaling distinctly promotes self-renewal and lymphoid differentiation in Dnmt3a-mutant hematopoietic stem cells, contributing to clonal hematopoiesis of indeterminate potential. See related article by SanMiguel et al., p. 2763 (3).]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[TNF receptor signaling distinctly promotes self-renewal and lymphoid differentiation in Dnmt3a-mutant hematopoietic stem cells, contributing to clonal hematopoiesis of indeterminate potential. See related article by SanMiguel et al., p. 2763 (3).]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[TNF receptor signaling distinctly promotes self-renewal and lymphoid differentiation in Dnmt3a-mutant hematopoietic stem cells, contributing to clonal hematopoiesis of indeterminate potential. See related article by SanMiguel et al., p. 2763 (3).]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[TNF receptor signaling distinctly promotes self-renewal and lymphoid differentiation in Dnmt3a-mutant hematopoietic stem cells, contributing to clonal hematopoiesis of indeterminate potential. See related article by SanMiguel et al., p. 2763 (3).]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[TNF receptor signaling distinctly promotes self-renewal and lymphoid differentiation in Dnmt3a-mutant hematopoietic stem cells, contributing to clonal hematopoiesis of indeterminate potential. See related article by SanMiguel et al., p. 2763 (3).]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[TNF receptor signaling distinctly promotes self-renewal and lymphoid differentiation in Dnmt3a-mutant hematopoietic stem cells, contributing to clonal hematopoiesis of indeterminate potential. See related article by SanMiguel et al., p. 2763 (3).]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[TNF receptor signaling distinctly promotes self-renewal and lymphoid differentiation in Dnmt3a-mutant hematopoietic stem cells, contributing to clonal hematopoiesis of indeterminate potential. See related article by SanMiguel et al., p. 2763 (3).]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[TNF receptor signaling distinctly promotes self-renewal and lymphoid differentiation in Dnmt3a-mutant hematopoietic stem cells, contributing to clonal hematopoiesis of indeterminate potential. See related article by SanMiguel et al., p. 2763 (3).]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221216195635&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to inferring the order in which mutations arise during cancer progression]]></title>
        <id>pubmed:36459515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36459515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yuan Gao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to inferring the order in which mutations arise during cancer progression]]></title>
        <id>pubmed:36459515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36459515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yuan Gao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Deep Dive into the Circulating ctDNA Cosmos to Vanquish Neuroblastoma]]></title>
        <id>pubmed:36458435</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458435/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hedwig E Deubzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to inferring the order in which mutations arise during cancer progression]]></title>
        <id>pubmed:36459515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36459515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yuan Gao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Deep Dive into the Circulating ctDNA Cosmos to Vanquish Neuroblastoma]]></title>
        <id>pubmed:36458435</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458435/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hedwig E Deubzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to inferring the order in which mutations arise during cancer progression]]></title>
        <id>pubmed:36459515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36459515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yuan Gao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Deep Dive into the Circulating ctDNA Cosmos to Vanquish Neuroblastoma]]></title>
        <id>pubmed:36458435</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458435/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hedwig E Deubzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to inferring the order in which mutations arise during cancer progression]]></title>
        <id>pubmed:36459515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36459515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yuan Gao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Deep Dive into the Circulating ctDNA Cosmos to Vanquish Neuroblastoma]]></title>
        <id>pubmed:36458435</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458435/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hedwig E Deubzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to inferring the order in which mutations arise during cancer progression]]></title>
        <id>pubmed:36459515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36459515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yuan Gao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Deep Dive into the Circulating ctDNA Cosmos to Vanquish Neuroblastoma]]></title>
        <id>pubmed:36458435</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458435/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hedwig E Deubzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to inferring the order in which mutations arise during cancer progression]]></title>
        <id>pubmed:36459515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36459515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yuan Gao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Deep Dive into the Circulating ctDNA Cosmos to Vanquish Neuroblastoma]]></title>
        <id>pubmed:36458435</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458435/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hedwig E Deubzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to inferring the order in which mutations arise during cancer progression]]></title>
        <id>pubmed:36459515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36459515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yuan Gao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Deep Dive into the Circulating ctDNA Cosmos to Vanquish Neuroblastoma]]></title>
        <id>pubmed:36458435</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458435/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hedwig E Deubzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TNF Receptors Choose HSC Fate in Supporting Dnmt3a-Mutant Clonal Hematopoiesis]]></title>
        <id>pubmed:36458433</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458433/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Katia E Nio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to inferring the order in which mutations arise during cancer progression]]></title>
        <id>pubmed:36459515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36459515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yuan Gao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Deep Dive into the Circulating ctDNA Cosmos to Vanquish Neuroblastoma]]></title>
        <id>pubmed:36458435</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458435/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hedwig E Deubzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to inferring the order in which mutations arise during cancer progression]]></title>
        <id>pubmed:36459515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36459515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yuan Gao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Deep Dive into the Circulating ctDNA Cosmos to Vanquish Neuroblastoma]]></title>
        <id>pubmed:36458435</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458435/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hedwig E Deubzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A phylogenetic approach to inferring the order in which mutations arise during cancer progression]]></title>
        <id>pubmed:36459515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36459515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yuan Gao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Deep Dive into the Circulating ctDNA Cosmos to Vanquish Neuroblastoma]]></title>
        <id>pubmed:36458435</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36458435/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-12-02T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hedwig E Deubzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the expansion of hematopoietic cells harboring leukemia-associated somatic mutations in otherwise healthy people and occurs in at least 10% of adults over 70. It is well established that people with CHIP have increased rates of hematologic malignancy, increased risk of cardiovascular disease (CVD), and worse all-cause mortality compared to those without CHIP. Despite recent advancements in understanding CHIP as it relates...]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230102195815&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) represents clonal expansion of mutated hematopoietic stem cells detectable in the peripheral blood or bone marrow through next generation sequencing. The current prevailing model posits that CH mutations detected in the peripheral blood mirror bone marrow mutations with clones widely disseminated across hematopoietic compartments. We sought to test the hypothesis that all clones are disseminated throughout hematopoietic tissues by comparing CH in hip versus peripheral...]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the expansion of hematopoietic cells harboring leukemia-associated somatic mutations in otherwise healthy people and occurs in at least 10% of adults over 70. It is well established that people with CHIP have increased rates of hematologic malignancy, increased risk of cardiovascular disease (CVD), and worse all-cause mortality compared to those without CHIP. Despite recent advancements in understanding CHIP as it relates...]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230101195858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) represents clonal expansion of mutated hematopoietic stem cells detectable in the peripheral blood or bone marrow through next generation sequencing. The current prevailing model posits that CH mutations detected in the peripheral blood mirror bone marrow mutations with clones widely disseminated across hematopoietic compartments. We sought to test the hypothesis that all clones are disseminated throughout hematopoietic tissues by comparing CH in hip versus peripheral...]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the expansion of hematopoietic cells harboring leukemia-associated somatic mutations in otherwise healthy people and occurs in at least 10% of adults over 70. It is well established that people with CHIP have increased rates of hematologic malignancy, increased risk of cardiovascular disease (CVD), and worse all-cause mortality compared to those without CHIP. Despite recent advancements in understanding CHIP as it relates...]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) represents clonal expansion of mutated hematopoietic stem cells detectable in the peripheral blood or bone marrow through next generation sequencing. The current prevailing model posits that CH mutations detected in the peripheral blood mirror bone marrow mutations with clones widely disseminated across hematopoietic compartments. We sought to test the hypothesis that all clones are disseminated throughout hematopoietic tissues by comparing CH in hip versus peripheral...]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the expansion of hematopoietic cells harboring leukemia-associated somatic mutations in otherwise healthy people and occurs in at least 10% of adults over 70. It is well established that people with CHIP have increased rates of hematologic malignancy, increased risk of cardiovascular disease (CVD), and worse all-cause mortality compared to those without CHIP. Despite recent advancements in understanding CHIP as it relates...]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) represents clonal expansion of mutated hematopoietic stem cells detectable in the peripheral blood or bone marrow through next generation sequencing. The current prevailing model posits that CH mutations detected in the peripheral blood mirror bone marrow mutations with clones widely disseminated across hematopoietic compartments. We sought to test the hypothesis that all clones are disseminated throughout hematopoietic tissues by comparing CH in hip versus peripheral...]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the expansion of hematopoietic cells harboring leukemia-associated somatic mutations in otherwise healthy people and occurs in at least 10% of adults over 70. It is well established that people with CHIP have increased rates of hematologic malignancy, increased risk of cardiovascular disease (CVD), and worse all-cause mortality compared to those without CHIP. Despite recent advancements in understanding CHIP as it relates...]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) represents clonal expansion of mutated hematopoietic stem cells detectable in the peripheral blood or bone marrow through next generation sequencing. The current prevailing model posits that CH mutations detected in the peripheral blood mirror bone marrow mutations with clones widely disseminated across hematopoietic compartments. We sought to test the hypothesis that all clones are disseminated throughout hematopoietic tissues by comparing CH in hip versus peripheral...]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the expansion of hematopoietic cells harboring leukemia-associated somatic mutations in otherwise healthy people and occurs in at least 10% of adults over 70. It is well established that people with CHIP have increased rates of hematologic malignancy, increased risk of cardiovascular disease (CVD), and worse all-cause mortality compared to those without CHIP. Despite recent advancements in understanding CHIP as it relates...]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) represents clonal expansion of mutated hematopoietic stem cells detectable in the peripheral blood or bone marrow through next generation sequencing. The current prevailing model posits that CH mutations detected in the peripheral blood mirror bone marrow mutations with clones widely disseminated across hematopoietic compartments. We sought to test the hypothesis that all clones are disseminated throughout hematopoietic tissues by comparing CH in hip versus peripheral...]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the expansion of hematopoietic cells harboring leukemia-associated somatic mutations in otherwise healthy people and occurs in at least 10% of adults over 70. It is well established that people with CHIP have increased rates of hematologic malignancy, increased risk of cardiovascular disease (CVD), and worse all-cause mortality compared to those without CHIP. Despite recent advancements in understanding CHIP as it relates...]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) represents clonal expansion of mutated hematopoietic stem cells detectable in the peripheral blood or bone marrow through next generation sequencing. The current prevailing model posits that CH mutations detected in the peripheral blood mirror bone marrow mutations with clones widely disseminated across hematopoietic compartments. We sought to test the hypothesis that all clones are disseminated throughout hematopoietic tissues by comparing CH in hip versus peripheral...]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the expansion of hematopoietic cells harboring leukemia-associated somatic mutations in otherwise healthy people and occurs in at least 10% of adults over 70. It is well established that people with CHIP have increased rates of hematologic malignancy, increased risk of cardiovascular disease (CVD), and worse all-cause mortality compared to those without CHIP. Despite recent advancements in understanding CHIP as it relates...]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) represents clonal expansion of mutated hematopoietic stem cells detectable in the peripheral blood or bone marrow through next generation sequencing. The current prevailing model posits that CH mutations detected in the peripheral blood mirror bone marrow mutations with clones widely disseminated across hematopoietic compartments. We sought to test the hypothesis that all clones are disseminated throughout hematopoietic tissues by comparing CH in hip versus peripheral...]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the expansion of hematopoietic cells harboring leukemia-associated somatic mutations in otherwise healthy people and occurs in at least 10% of adults over 70. It is well established that people with CHIP have increased rates of hematologic malignancy, increased risk of cardiovascular disease (CVD), and worse all-cause mortality compared to those without CHIP. Despite recent advancements in understanding CHIP as it relates...]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) represents clonal expansion of mutated hematopoietic stem cells detectable in the peripheral blood or bone marrow through next generation sequencing. The current prevailing model posits that CH mutations detected in the peripheral blood mirror bone marrow mutations with clones widely disseminated across hematopoietic compartments. We sought to test the hypothesis that all clones are disseminated throughout hematopoietic tissues by comparing CH in hip versus peripheral...]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the expansion of hematopoietic cells harboring leukemia-associated somatic mutations in otherwise healthy people and occurs in at least 10% of adults over 70. It is well established that people with CHIP have increased rates of hematologic malignancy, increased risk of cardiovascular disease (CVD), and worse all-cause mortality compared to those without CHIP. Despite recent advancements in understanding CHIP as it relates...]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) represents clonal expansion of mutated hematopoietic stem cells detectable in the peripheral blood or bone marrow through next generation sequencing. The current prevailing model posits that CH mutations detected in the peripheral blood mirror bone marrow mutations with clones widely disseminated across hematopoietic compartments. We sought to test the hypothesis that all clones are disseminated throughout hematopoietic tissues by comparing CH in hip versus peripheral...]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the expansion of hematopoietic cells harboring leukemia-associated somatic mutations in otherwise healthy people and occurs in at least 10% of adults over 70. It is well established that people with CHIP have increased rates of hematologic malignancy, increased risk of cardiovascular disease (CVD), and worse all-cause mortality compared to those without CHIP. Despite recent advancements in understanding CHIP as it relates...]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) represents clonal expansion of mutated hematopoietic stem cells detectable in the peripheral blood or bone marrow through next generation sequencing. The current prevailing model posits that CH mutations detected in the peripheral blood mirror bone marrow mutations with clones widely disseminated across hematopoietic compartments. We sought to test the hypothesis that all clones are disseminated throughout hematopoietic tissues by comparing CH in hip versus peripheral...]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221216195635&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221216195635&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CHIP Happens: Clonal hematopoiesis of indeterminate potential and its relationship to solid tumors]]></title>
        <id>pubmed:36454121</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36454121/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221201200047&amp;v=2.17.8"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the expansion of hematopoietic cells harboring leukemia-associated somatic mutations in otherwise healthy people and occurs in at least 10% of adults over 70. It is well established that people with CHIP have increased rates of hematologic malignancy, increased risk of cardiovascular disease (CVD), and worse all-cause mortality compared to those without CHIP. Despite recent advancements in understanding CHIP as it relates...]]></summary>
        <author>
            <name>Sarah C Reed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones]]></title>
        <id>pubmed:36453641</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36453641/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221201200047&amp;v=2.17.8"/>
        <updated>2022-12-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) represents clonal expansion of mutated hematopoietic stem cells detectable in the peripheral blood or bone marrow through next generation sequencing. The current prevailing model posits that CH mutations detected in the peripheral blood mirror bone marrow mutations with clones widely disseminated across hematopoietic compartments. We sought to test the hypothesis that all clones are disseminated throughout hematopoietic tissues by comparing CH in hip versus peripheral...]]></summary>
        <author>
            <name>Afaf Osman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221231200754&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal haematopoiesis involves the expansion of certain blood cell lineages and has been associated with ageing and adverse health outcomes^(1-5). Here we use exome sequence data on 628,388 individuals to identify 40,208 carriers of clonal haematopoiesis of indeterminate potential (CHIP). Using genome-wide and exome-wide association analyses, we identify 24 loci (21 of which are novel) where germline genetic variation influences predisposition to CHIP, including missense variants in the...]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221230195728&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal haematopoiesis involves the expansion of certain blood cell lineages and has been associated with ageing and adverse health outcomes^(1-5). Here we use exome sequence data on 628,388 individuals to identify 40,208 carriers of clonal haematopoiesis of indeterminate potential (CHIP). Using genome-wide and exome-wide association analyses, we identify 24 loci (21 of which are novel) where germline genetic variation influences predisposition to CHIP, including missense variants in the...]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal haematopoiesis involves the expansion of certain blood cell lineages and has been associated with ageing and adverse health outcomes^(1-5). Here we use exome sequence data on 628,388 individuals to identify 40,208 carriers of clonal haematopoiesis of indeterminate potential (CHIP). Using genome-wide and exome-wide association analyses, we identify 24 loci (21 of which are novel) where germline genetic variation influences predisposition to CHIP, including missense variants in the...]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221229195927&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with increased mutational burden in every tissue studied. Occasionally, fitness-increasing mutations will arise, leading to stem cell clonal expansion. This process occurs in several tissues but has been best studied in blood. Clonal hematopoiesis is associated with an increased risk of blood cancers, such as acute myeloid leukemia, which result if additional cooperating mutations occur. Surprisingly, it is also associated with an increased risk of nonmalignant diseases, such...]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal haematopoiesis involves the expansion of certain blood cell lineages and has been associated with ageing and adverse health outcomes^(1-5). Here we use exome sequence data on 628,388 individuals to identify 40,208 carriers of clonal haematopoiesis of indeterminate potential (CHIP). Using genome-wide and exome-wide association analyses, we identify 24 loci (21 of which are novel) where germline genetic variation influences predisposition to CHIP, including missense variants in the...]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221228195929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with increased mutational burden in every tissue studied. Occasionally, fitness-increasing mutations will arise, leading to stem cell clonal expansion. This process occurs in several tissues but has been best studied in blood. Clonal hematopoiesis is associated with an increased risk of blood cancers, such as acute myeloid leukemia, which result if additional cooperating mutations occur. Surprisingly, it is also associated with an increased risk of nonmalignant diseases, such...]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal haematopoiesis involves the expansion of certain blood cell lineages and has been associated with ageing and adverse health outcomes^(1-5). Here we use exome sequence data on 628,388 individuals to identify 40,208 carriers of clonal haematopoiesis of indeterminate potential (CHIP). Using genome-wide and exome-wide association analyses, we identify 24 loci (21 of which are novel) where germline genetic variation influences predisposition to CHIP, including missense variants in the...]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221227195809&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with increased mutational burden in every tissue studied. Occasionally, fitness-increasing mutations will arise, leading to stem cell clonal expansion. This process occurs in several tissues but has been best studied in blood. Clonal hematopoiesis is associated with an increased risk of blood cancers, such as acute myeloid leukemia, which result if additional cooperating mutations occur. Surprisingly, it is also associated with an increased risk of nonmalignant diseases, such...]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal haematopoiesis involves the expansion of certain blood cell lineages and has been associated with ageing and adverse health outcomes^(1-5). Here we use exome sequence data on 628,388 individuals to identify 40,208 carriers of clonal haematopoiesis of indeterminate potential (CHIP). Using genome-wide and exome-wide association analyses, we identify 24 loci (21 of which are novel) where germline genetic variation influences predisposition to CHIP, including missense variants in the...]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221226195830&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with increased mutational burden in every tissue studied. Occasionally, fitness-increasing mutations will arise, leading to stem cell clonal expansion. This process occurs in several tissues but has been best studied in blood. Clonal hematopoiesis is associated with an increased risk of blood cancers, such as acute myeloid leukemia, which result if additional cooperating mutations occur. Surprisingly, it is also associated with an increased risk of nonmalignant diseases, such...]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal haematopoiesis involves the expansion of certain blood cell lineages and has been associated with ageing and adverse health outcomes^(1-5). Here we use exome sequence data on 628,388 individuals to identify 40,208 carriers of clonal haematopoiesis of indeterminate potential (CHIP). Using genome-wide and exome-wide association analyses, we identify 24 loci (21 of which are novel) where germline genetic variation influences predisposition to CHIP, including missense variants in the...]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with increased mutational burden in every tissue studied. Occasionally, fitness-increasing mutations will arise, leading to stem cell clonal expansion. This process occurs in several tissues but has been best studied in blood. Clonal hematopoiesis is associated with an increased risk of blood cancers, such as acute myeloid leukemia, which result if additional cooperating mutations occur. Surprisingly, it is also associated with an increased risk of nonmalignant diseases, such...]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal haematopoiesis involves the expansion of certain blood cell lineages and has been associated with ageing and adverse health outcomes^(1-5). Here we use exome sequence data on 628,388 individuals to identify 40,208 carriers of clonal haematopoiesis of indeterminate potential (CHIP). Using genome-wide and exome-wide association analyses, we identify 24 loci (21 of which are novel) where germline genetic variation influences predisposition to CHIP, including missense variants in the...]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with increased mutational burden in every tissue studied. Occasionally, fitness-increasing mutations will arise, leading to stem cell clonal expansion. This process occurs in several tissues but has been best studied in blood. Clonal hematopoiesis is associated with an increased risk of blood cancers, such as acute myeloid leukemia, which result if additional cooperating mutations occur. Surprisingly, it is also associated with an increased risk of nonmalignant diseases, such...]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal haematopoiesis involves the expansion of certain blood cell lineages and has been associated with ageing and adverse health outcomes^(1-5). Here we use exome sequence data on 628,388 individuals to identify 40,208 carriers of clonal haematopoiesis of indeterminate potential (CHIP). Using genome-wide and exome-wide association analyses, we identify 24 loci (21 of which are novel) where germline genetic variation influences predisposition to CHIP, including missense variants in the...]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with increased mutational burden in every tissue studied. Occasionally, fitness-increasing mutations will arise, leading to stem cell clonal expansion. This process occurs in several tissues but has been best studied in blood. Clonal hematopoiesis is associated with an increased risk of blood cancers, such as acute myeloid leukemia, which result if additional cooperating mutations occur. Surprisingly, it is also associated with an increased risk of nonmalignant diseases, such...]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221216195635&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221216195635&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Common and rare variant associations with clonal haematopoiesis phenotypes]]></title>
        <id>pubmed:36450978</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450978/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Michael D Kessler</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Its Impact on Human Health]]></title>
        <id>pubmed:36450282</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36450282/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221201200047&amp;v=2.17.8"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is associated with increased mutational burden in every tissue studied. Occasionally, fitness-increasing mutations will arise, leading to stem cell clonal expansion. This process occurs in several tissues but has been best studied in blood. Clonal hematopoiesis is associated with an increased risk of blood cancers, such as acute myeloid leukemia, which result if additional cooperating mutations occur. Surprisingly, it is also associated with an increased risk of nonmalignant diseases, such...]]></summary>
        <author>
            <name>Herra Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic Mutational Landscape of CSF Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases]]></title>
        <id>pubmed:36449664</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36449664/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>N Ari Wijetunga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic Mutational Landscape of CSF Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases]]></title>
        <id>pubmed:36449664</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36449664/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>N Ari Wijetunga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic Mutational Landscape of CSF Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases]]></title>
        <id>pubmed:36449664</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36449664/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>N Ari Wijetunga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic Mutational Landscape of CSF Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases]]></title>
        <id>pubmed:36449664</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36449664/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>N Ari Wijetunga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic Mutational Landscape of CSF Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases]]></title>
        <id>pubmed:36449664</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36449664/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>N Ari Wijetunga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic Mutational Landscape of CSF Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases]]></title>
        <id>pubmed:36449664</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36449664/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>N Ari Wijetunga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic Mutational Landscape of CSF Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases]]></title>
        <id>pubmed:36449664</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36449664/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>N Ari Wijetunga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic Mutational Landscape of CSF Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases]]></title>
        <id>pubmed:36449664</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36449664/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>N Ari Wijetunga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic Mutational Landscape of CSF Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases]]></title>
        <id>pubmed:36449664</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36449664/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>N Ari Wijetunga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic Mutational Landscape of CSF Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases]]></title>
        <id>pubmed:36449664</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36449664/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221201200049&amp;v=2.17.8"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In solid tumor LM patients undergoing pCSI, we found unique genomic profiles associated with pCSI through CSF ctDNA analyses. Patients with reduced genomic diversity within the CSF demonstrated improved OS after pCSI suggesting that CSF ctDNA analysis may have use in predicting pCSI response.]]></summary>
        <author>
            <name>N Ari Wijetunga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic Mutational Landscape of CSF Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases]]></title>
        <id>pubmed:36449664</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36449664/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-30T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In solid tumor LM patients undergoing pCSI, we found unique genomic profiles associated with pCSI through CSF ctDNA analyses. Patients with reduced genomic diversity within the CSF demonstrated improved OS after pCSI suggesting that CSF ctDNA analysis may have use in predicting pCSI response.]]></summary>
        <author>
            <name>N Ari Wijetunga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is common among older people and associated with an increased risk of atherosclerosis, inflammation, and shorter overall survival. Age and inflammation are major risk factors for ischemic stroke, yet the association of CH with risk of secondary vascular events and death is unknown. We investigated CH in peripheral blood DNA from 581 patients with first-ever ischemic stroke from the Prospective Cohort with Incident Stroke-Berlin study (PROSCIS-B) using error-corrected...]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221225195852&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA released into the bloodstream primarily from cancer cells undergoing apoptosis. In metastatic castration-resistant prostate cancer (mCRPC), characterizing genomic alterations in ctDNA identifies mutations, copy number alterations, and structural rearrangements with predictive and prognostic biomarker utility. These associations with clinical outcomes have resulted in ctDNA increasingly incorporated into routine...]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is common among older people and associated with an increased risk of atherosclerosis, inflammation, and shorter overall survival. Age and inflammation are major risk factors for ischemic stroke, yet the association of CH with risk of secondary vascular events and death is unknown. We investigated CH in peripheral blood DNA from 581 patients with first-ever ischemic stroke from the Prospective Cohort with Incident Stroke-Berlin study (PROSCIS-B) using error-corrected...]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221224200048&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA released into the bloodstream primarily from cancer cells undergoing apoptosis. In metastatic castration-resistant prostate cancer (mCRPC), characterizing genomic alterations in ctDNA identifies mutations, copy number alterations, and structural rearrangements with predictive and prognostic biomarker utility. These associations with clinical outcomes have resulted in ctDNA increasingly incorporated into routine...]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is common among older people and associated with an increased risk of atherosclerosis, inflammation, and shorter overall survival. Age and inflammation are major risk factors for ischemic stroke, yet the association of CH with risk of secondary vascular events and death is unknown. We investigated CH in peripheral blood DNA from 581 patients with first-ever ischemic stroke from the Prospective Cohort with Incident Stroke-Berlin study (PROSCIS-B) using error-corrected...]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221223195335&amp;v=2.17.9.post6+86293ac"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA released into the bloodstream primarily from cancer cells undergoing apoptosis. In metastatic castration-resistant prostate cancer (mCRPC), characterizing genomic alterations in ctDNA identifies mutations, copy number alterations, and structural rearrangements with predictive and prognostic biomarker utility. These associations with clinical outcomes have resulted in ctDNA increasingly incorporated into routine...]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221222195718&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221221195909&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221220195556&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221219195955&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221216195635&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221216195635&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221201200047&amp;v=2.17.8"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is common among older people and associated with an increased risk of atherosclerosis, inflammation, and shorter overall survival. Age and inflammation are major risk factors for ischemic stroke, yet the association of CH with risk of secondary vascular events and death is unknown. We investigated CH in peripheral blood DNA from 581 patients with first-ever ischemic stroke from the Prospective Cohort with Incident Stroke-Berlin study (PROSCIS-B) using error-corrected...]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221201200047&amp;v=2.17.8"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA released into the bloodstream primarily from cancer cells undergoing apoptosis. In metastatic castration-resistant prostate cancer (mCRPC), characterizing genomic alterations in ctDNA identifies mutations, copy number alterations, and structural rearrangements with predictive and prognostic biomarker utility. These associations with clinical outcomes have resulted in ctDNA increasingly incorporated into routine...]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is common among older people and associated with an increased risk of atherosclerosis, inflammation, and shorter overall survival. Age and inflammation are major risk factors for ischemic stroke, yet the association of CH with risk of secondary vascular events and death is unknown. We investigated CH in peripheral blood DNA from 581 patients with first-ever ischemic stroke from the Prospective Cohort with Incident Stroke-Berlin study (PROSCIS-B) using error-corrected...]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA released into the bloodstream primarily from cancer cells undergoing apoptosis. In metastatic castration-resistant prostate cancer (mCRPC), characterizing genomic alterations in ctDNA identifies mutations, copy number alterations, and structural rearrangements with predictive and prognostic biomarker utility. These associations with clinical outcomes have resulted in ctDNA increasingly incorporated into routine...]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is common among older people and associated with an increased risk of atherosclerosis, inflammation, and shorter overall survival. Age and inflammation are major risk factors for ischemic stroke, yet the association of CH with risk of secondary vascular events and death is unknown. We investigated CH in peripheral blood DNA from 581 patients with first-ever ischemic stroke from the Prospective Cohort with Incident Stroke-Berlin study (PROSCIS-B) using error-corrected...]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA released into the bloodstream primarily from cancer cells undergoing apoptosis. In metastatic castration-resistant prostate cancer (mCRPC), characterizing genomic alterations in ctDNA identifies mutations, copy number alterations, and structural rearrangements with predictive and prognostic biomarker utility. These associations with clinical outcomes have resulted in ctDNA increasingly incorporated into routine...]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke]]></title>
        <id>pubmed:36441964</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36441964/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is common among older people and associated with an increased risk of atherosclerosis, inflammation, and shorter overall survival. Age and inflammation are major risk factors for ischemic stroke, yet the association of CH with risk of secondary vascular events and death is unknown. We investigated CH in peripheral blood DNA from 581 patients with first-ever ischemic stroke from the Prospective Cohort with Incident Stroke-Berlin study (PROSCIS-B) using error-corrected...]]></summary>
        <author>
            <name>Christopher Maximilian Arends</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation]]></title>
        <id>pubmed:36439451</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439451/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA released into the bloodstream primarily from cancer cells undergoing apoptosis. In metastatic castration-resistant prostate cancer (mCRPC), characterizing genomic alterations in ctDNA identifies mutations, copy number alterations, and structural rearrangements with predictive and prognostic biomarker utility. These associations with clinical outcomes have resulted in ctDNA increasingly incorporated into routine...]]></summary>
        <author>
            <name>Edmond M Kwan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational patterns along different evolution paths of follicular lymphoma]]></title>
        <id>pubmed:36439408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Miri Michaeli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational patterns along different evolution paths of follicular lymphoma]]></title>
        <id>pubmed:36439408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Miri Michaeli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational patterns along different evolution paths of follicular lymphoma]]></title>
        <id>pubmed:36439408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Miri Michaeli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational patterns along different evolution paths of follicular lymphoma]]></title>
        <id>pubmed:36439408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Miri Michaeli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational patterns along different evolution paths of follicular lymphoma]]></title>
        <id>pubmed:36439408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Miri Michaeli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational patterns along different evolution paths of follicular lymphoma]]></title>
        <id>pubmed:36439408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Miri Michaeli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational patterns along different evolution paths of follicular lymphoma]]></title>
        <id>pubmed:36439408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Miri Michaeli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational patterns along different evolution paths of follicular lymphoma]]></title>
        <id>pubmed:36439408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Miri Michaeli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational patterns along different evolution paths of follicular lymphoma]]></title>
        <id>pubmed:36439408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Miri Michaeli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational patterns along different evolution paths of follicular lymphoma]]></title>
        <id>pubmed:36439408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221201200049&amp;v=2.17.8"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) is an indolent disease, characterized by a median life expectancy of 18-20 years and by intermittent periods of relapse and remission. FL frequently transforms into the more aggressive diffuse large B cell lymphoma (t-FL). In previous studies, the analysis of immunoglobulin heavy chain variable region (IgHV) genes in sequential biopsies from the same patient revealed two different patterns of tumor clonal evolution: direct evolution, through acquisition of additional...]]></summary>
        <author>
            <name>Miri Michaeli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational patterns along different evolution paths of follicular lymphoma]]></title>
        <id>pubmed:36439408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) is an indolent disease, characterized by a median life expectancy of 18-20 years and by intermittent periods of relapse and remission. FL frequently transforms into the more aggressive diffuse large B cell lymphoma (t-FL). In previous studies, the analysis of immunoglobulin heavy chain variable region (IgHV) genes in sequential biopsies from the same patient revealed two different patterns of tumor clonal evolution: direct evolution, through acquisition of additional...]]></summary>
        <author>
            <name>Miri Michaeli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational patterns along different evolution paths of follicular lymphoma]]></title>
        <id>pubmed:36439408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) is an indolent disease, characterized by a median life expectancy of 18-20 years and by intermittent periods of relapse and remission. FL frequently transforms into the more aggressive diffuse large B cell lymphoma (t-FL). In previous studies, the analysis of immunoglobulin heavy chain variable region (IgHV) genes in sequential biopsies from the same patient revealed two different patterns of tumor clonal evolution: direct evolution, through acquisition of additional...]]></summary>
        <author>
            <name>Miri Michaeli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational patterns along different evolution paths of follicular lymphoma]]></title>
        <id>pubmed:36439408</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36439408/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-28T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) is an indolent disease, characterized by a median life expectancy of 18-20 years and by intermittent periods of relapse and remission. FL frequently transforms into the more aggressive diffuse large B cell lymphoma (t-FL). In previous studies, the analysis of immunoglobulin heavy chain variable region (IgHV) genes in sequential biopsies from the same patient revealed two different patterns of tumor clonal evolution: direct evolution, through acquisition of additional...]]></summary>
        <author>
            <name>Miri Michaeli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221218195619&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221217195811&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221216195635&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221201200047&amp;v=2.17.8"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the presence of clones of mutated blood cells without overt blood diseases. In the last few years, it has emerged that CHIP is associated with atherosclerosis and coronary calcification and that it is an independent determinant of cardiovascular mortality. Recently, CHIP has been found to occur frequently in patients with calcific aortic valve disease (CAVD) and it is associated with a poor prognosis after valve...]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the presence of clones of mutated blood cells without overt blood diseases. In the last few years, it has emerged that CHIP is associated with atherosclerosis and coronary calcification and that it is an independent determinant of cardiovascular mortality. Recently, CHIP has been found to occur frequently in patients with calcific aortic valve disease (CAVD) and it is associated with a poor prognosis after valve...]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the presence of clones of mutated blood cells without overt blood diseases. In the last few years, it has emerged that CHIP is associated with atherosclerosis and coronary calcification and that it is an independent determinant of cardiovascular mortality. Recently, CHIP has been found to occur frequently in patients with calcific aortic valve disease (CAVD) and it is associated with a poor prognosis after valve...]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers]]></title>
        <id>pubmed:36437309</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36437309/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the presence of clones of mutated blood cells without overt blood diseases. In the last few years, it has emerged that CHIP is associated with atherosclerosis and coronary calcification and that it is an independent determinant of cardiovascular mortality. Recently, CHIP has been found to occur frequently in patients with calcific aortic valve disease (CAVD) and it is associated with a poor prognosis after valve...]]></summary>
        <author>
            <name>Francesco Vieceli Dalla Sega</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221216195635&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221215195748&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221214200254&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221213200118&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221212200524&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221201200047&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The BM, the major hematopoietic organ in humans, consists of a pleiomorphic environment of cellular, extracellular, and bioactive compounds with continuous and complex interactions between them, leading to the formation of mature blood cells found in the peripheral circulation. Systemic and local inflammation in the BM elicit stress hematopoiesis and drive hematopoietic stem cells (HSCs) out of their quiescent state, as part of a protective pathophysiologic process. However, sustained chronic...]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221201200047&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal hematological neoplasms characterized by ineffective hematopoiesis in one or more bone marrow cell lineages. Consequently, patients present with variable degrees of cytopenia and dysplasia. These characteristics constitute the basis for the World Health Organization (WHO) classification criteria of MDS, among other parameters, for the current prognostic scoring system. Although nearly half of newly diagnosed patients present a cytogenetic...]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The BM, the major hematopoietic organ in humans, consists of a pleiomorphic environment of cellular, extracellular, and bioactive compounds with continuous and complex interactions between them, leading to the formation of mature blood cells found in the peripheral circulation. Systemic and local inflammation in the BM elicit stress hematopoiesis and drive hematopoietic stem cells (HSCs) out of their quiescent state, as part of a protective pathophysiologic process. However, sustained chronic...]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal hematological neoplasms characterized by ineffective hematopoiesis in one or more bone marrow cell lineages. Consequently, patients present with variable degrees of cytopenia and dysplasia. These characteristics constitute the basis for the World Health Organization (WHO) classification criteria of MDS, among other parameters, for the current prognostic scoring system. Although nearly half of newly diagnosed patients present a cytogenetic...]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The BM, the major hematopoietic organ in humans, consists of a pleiomorphic environment of cellular, extracellular, and bioactive compounds with continuous and complex interactions between them, leading to the formation of mature blood cells found in the peripheral circulation. Systemic and local inflammation in the BM elicit stress hematopoiesis and drive hematopoietic stem cells (HSCs) out of their quiescent state, as part of a protective pathophysiologic process. However, sustained chronic...]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal hematological neoplasms characterized by ineffective hematopoiesis in one or more bone marrow cell lineages. Consequently, patients present with variable degrees of cytopenia and dysplasia. These characteristics constitute the basis for the World Health Organization (WHO) classification criteria of MDS, among other parameters, for the current prognostic scoring system. Although nearly half of newly diagnosed patients present a cytogenetic...]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The BM, the major hematopoietic organ in humans, consists of a pleiomorphic environment of cellular, extracellular, and bioactive compounds with continuous and complex interactions between them, leading to the formation of mature blood cells found in the peripheral circulation. Systemic and local inflammation in the BM elicit stress hematopoiesis and drive hematopoietic stem cells (HSCs) out of their quiescent state, as part of a protective pathophysiologic process. However, sustained chronic...]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal hematological neoplasms characterized by ineffective hematopoiesis in one or more bone marrow cell lineages. Consequently, patients present with variable degrees of cytopenia and dysplasia. These characteristics constitute the basis for the World Health Organization (WHO) classification criteria of MDS, among other parameters, for the current prognostic scoring system. Although nearly half of newly diagnosed patients present a cytogenetic...]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The BM, the major hematopoietic organ in humans, consists of a pleiomorphic environment of cellular, extracellular, and bioactive compounds with continuous and complex interactions between them, leading to the formation of mature blood cells found in the peripheral circulation. Systemic and local inflammation in the BM elicit stress hematopoiesis and drive hematopoietic stem cells (HSCs) out of their quiescent state, as part of a protective pathophysiologic process. However, sustained chronic...]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal hematological neoplasms characterized by ineffective hematopoiesis in one or more bone marrow cell lineages. Consequently, patients present with variable degrees of cytopenia and dysplasia. These characteristics constitute the basis for the World Health Organization (WHO) classification criteria of MDS, among other parameters, for the current prognostic scoring system. Although nearly half of newly diagnosed patients present a cytogenetic...]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes]]></title>
        <id>pubmed:36428749</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428749/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The BM, the major hematopoietic organ in humans, consists of a pleiomorphic environment of cellular, extracellular, and bioactive compounds with continuous and complex interactions between them, leading to the formation of mature blood cells found in the peripheral circulation. Systemic and local inflammation in the BM elicit stress hematopoiesis and drive hematopoietic stem cells (HSCs) out of their quiescent state, as part of a protective pathophysiologic process. However, sustained chronic...]]></summary>
        <author>
            <name>Olga Kouroukli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment]]></title>
        <id>pubmed:36428627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of clonal hematological neoplasms characterized by ineffective hematopoiesis in one or more bone marrow cell lineages. Consequently, patients present with variable degrees of cytopenia and dysplasia. These characteristics constitute the basis for the World Health Organization (WHO) classification criteria of MDS, among other parameters, for the current prognostic scoring system. Although nearly half of newly diagnosed patients present a cytogenetic...]]></summary>
        <author>
            <name>Pamela Acha</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluating cancer etiology and risk with a mathematical model of tumor evolution]]></title>
        <id>pubmed:36433937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36433937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sophie Pnisson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluating cancer etiology and risk with a mathematical model of tumor evolution]]></title>
        <id>pubmed:36433937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36433937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sophie Pnisson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia]]></title>
        <id>pubmed:36430731</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36430731/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Davide Bagnara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms]]></title>
        <id>pubmed:36428782</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428782/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluating cancer etiology and risk with a mathematical model of tumor evolution]]></title>
        <id>pubmed:36433937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36433937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sophie Pnisson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia]]></title>
        <id>pubmed:36430731</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36430731/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Davide Bagnara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms]]></title>
        <id>pubmed:36428782</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428782/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluating cancer etiology and risk with a mathematical model of tumor evolution]]></title>
        <id>pubmed:36433937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36433937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sophie Pnisson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia]]></title>
        <id>pubmed:36430731</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36430731/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Davide Bagnara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms]]></title>
        <id>pubmed:36428782</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428782/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluating cancer etiology and risk with a mathematical model of tumor evolution]]></title>
        <id>pubmed:36433937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36433937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sophie Pnisson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia]]></title>
        <id>pubmed:36430731</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36430731/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Davide Bagnara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms]]></title>
        <id>pubmed:36428782</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428782/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluating cancer etiology and risk with a mathematical model of tumor evolution]]></title>
        <id>pubmed:36433937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36433937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sophie Pnisson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia]]></title>
        <id>pubmed:36430731</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36430731/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Davide Bagnara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms]]></title>
        <id>pubmed:36428782</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428782/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluating cancer etiology and risk with a mathematical model of tumor evolution]]></title>
        <id>pubmed:36433937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36433937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Sophie Pnisson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia]]></title>
        <id>pubmed:36430731</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36430731/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Davide Bagnara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms]]></title>
        <id>pubmed:36428782</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428782/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluating cancer etiology and risk with a mathematical model of tumor evolution]]></title>
        <id>pubmed:36433937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36433937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221201200049&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence arising from DNA sequencing of healthy human tissues has clearly indicated that our organs accumulate a relevant number of somatic mutations due to normal endogenous mutational processes, in addition to those caused by environmental factors. A deeper understanding of the evolution of this endogenous mutational load is critical for understanding what causes cancer. Here we present a mathematical model of tumor evolution that is able to predict the expected number of endogenous...]]></summary>
        <author>
            <name>Sophie Pnisson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia]]></title>
        <id>pubmed:36430731</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36430731/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221201200049&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The engagement of the B cell receptor (BcR) on the surface of leukemic cells represents a key event in chronic lymphocytic leukemia (CLL) since it can lead to the maintenance and expansion of the neoplastic clone. This notion was initially suggested by observations of the CLL BcR repertoire and of correlations existing between certain BcR features and the clinical outcomes of single patients. Based on these observations, tyrosine kinase inhibitors (TKIs), which block BcR signaling, have been...]]></summary>
        <author>
            <name>Davide Bagnara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms]]></title>
        <id>pubmed:36428782</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428782/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221201200049&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Until recently, conventional prognostication of myelodysplastic neoplasms (MDS) was performed using the revised International Prognostic Scoring System (IPSS-R), with additional adverse prognoses conferred by select mutations. Nonetheless, the clonal diversity and dynamics of coexisting mutations have been shown to alter the prognosis and treatment response in patients with MDS. Often in the process of clonal evolution, various initial hits are preferentially followed by a specific spectrum of...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluating cancer etiology and risk with a mathematical model of tumor evolution]]></title>
        <id>pubmed:36433937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36433937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence arising from DNA sequencing of healthy human tissues has clearly indicated that our organs accumulate a relevant number of somatic mutations due to normal endogenous mutational processes, in addition to those caused by environmental factors. A deeper understanding of the evolution of this endogenous mutational load is critical for understanding what causes cancer. Here we present a mathematical model of tumor evolution that is able to predict the expected number of endogenous...]]></summary>
        <author>
            <name>Sophie Pnisson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia]]></title>
        <id>pubmed:36430731</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36430731/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The engagement of the B cell receptor (BcR) on the surface of leukemic cells represents a key event in chronic lymphocytic leukemia (CLL) since it can lead to the maintenance and expansion of the neoplastic clone. This notion was initially suggested by observations of the CLL BcR repertoire and of correlations existing between certain BcR features and the clinical outcomes of single patients. Based on these observations, tyrosine kinase inhibitors (TKIs), which block BcR signaling, have been...]]></summary>
        <author>
            <name>Davide Bagnara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms]]></title>
        <id>pubmed:36428782</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428782/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Until recently, conventional prognostication of myelodysplastic neoplasms (MDS) was performed using the revised International Prognostic Scoring System (IPSS-R), with additional adverse prognoses conferred by select mutations. Nonetheless, the clonal diversity and dynamics of coexisting mutations have been shown to alter the prognosis and treatment response in patients with MDS. Often in the process of clonal evolution, various initial hits are preferentially followed by a specific spectrum of...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluating cancer etiology and risk with a mathematical model of tumor evolution]]></title>
        <id>pubmed:36433937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36433937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence arising from DNA sequencing of healthy human tissues has clearly indicated that our organs accumulate a relevant number of somatic mutations due to normal endogenous mutational processes, in addition to those caused by environmental factors. A deeper understanding of the evolution of this endogenous mutational load is critical for understanding what causes cancer. Here we present a mathematical model of tumor evolution that is able to predict the expected number of endogenous...]]></summary>
        <author>
            <name>Sophie Pnisson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia]]></title>
        <id>pubmed:36430731</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36430731/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The engagement of the B cell receptor (BcR) on the surface of leukemic cells represents a key event in chronic lymphocytic leukemia (CLL) since it can lead to the maintenance and expansion of the neoplastic clone. This notion was initially suggested by observations of the CLL BcR repertoire and of correlations existing between certain BcR features and the clinical outcomes of single patients. Based on these observations, tyrosine kinase inhibitors (TKIs), which block BcR signaling, have been...]]></summary>
        <author>
            <name>Davide Bagnara</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms]]></title>
        <id>pubmed:36428782</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428782/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Until recently, conventional prognostication of myelodysplastic neoplasms (MDS) was performed using the revised International Prognostic Scoring System (IPSS-R), with additional adverse prognoses conferred by select mutations. Nonetheless, the clonal diversity and dynamics of coexisting mutations have been shown to alter the prognosis and treatment response in patients with MDS. Often in the process of clonal evolution, various initial hits are preferentially followed by a specific spectrum of...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluating cancer etiology and risk with a mathematical model of tumor evolution]]></title>
        <id>pubmed:36433937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36433937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence arising from DNA sequencing of healthy human tissues has clearly indicated that our organs accumulate a relevant number of somatic mutations due to normal endogenous mutational processes, in addition to those caused by environmental factors. A deeper understanding of the evolution of this endogenous mutational load is critical for understanding what causes cancer. Here we present a mathematical model of tumor evolution that is able to predict the expected number of endogenous...]]></summary>
        <author>
            <name>Sophie Pnisson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms]]></title>
        <id>pubmed:36428782</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428782/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Until recently, conventional prognostication of myelodysplastic neoplasms (MDS) was performed using the revised International Prognostic Scoring System (IPSS-R), with additional adverse prognoses conferred by select mutations. Nonetheless, the clonal diversity and dynamics of coexisting mutations have been shown to alter the prognosis and treatment response in patients with MDS. Often in the process of clonal evolution, various initial hits are preferentially followed by a specific spectrum of...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluating cancer etiology and risk with a mathematical model of tumor evolution]]></title>
        <id>pubmed:36433937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36433937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence arising from DNA sequencing of healthy human tissues has clearly indicated that our organs accumulate a relevant number of somatic mutations due to normal endogenous mutational processes, in addition to those caused by environmental factors. A deeper understanding of the evolution of this endogenous mutational load is critical for understanding what causes cancer. Here we present a mathematical model of tumor evolution that is able to predict the expected number of endogenous...]]></summary>
        <author>
            <name>Sophie Pnisson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms]]></title>
        <id>pubmed:36428782</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428782/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Until recently, conventional prognostication of myelodysplastic neoplasms (MDS) was performed using the revised International Prognostic Scoring System (IPSS-R), with additional adverse prognoses conferred by select mutations. Nonetheless, the clonal diversity and dynamics of coexisting mutations have been shown to alter the prognosis and treatment response in patients with MDS. Often in the process of clonal evolution, various initial hits are preferentially followed by a specific spectrum of...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evaluating cancer etiology and risk with a mathematical model of tumor evolution]]></title>
        <id>pubmed:36433937</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36433937/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence arising from DNA sequencing of healthy human tissues has clearly indicated that our organs accumulate a relevant number of somatic mutations due to normal endogenous mutational processes, in addition to those caused by environmental factors. A deeper understanding of the evolution of this endogenous mutational load is critical for understanding what causes cancer. Here we present a mathematical model of tumor evolution that is able to predict the expected number of endogenous...]]></summary>
        <author>
            <name>Sophie Pnisson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms]]></title>
        <id>pubmed:36428782</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36428782/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Until recently, conventional prognostication of myelodysplastic neoplasms (MDS) was performed using the revised International Prognostic Scoring System (IPSS-R), with additional adverse prognoses conferred by select mutations. Nonetheless, the clonal diversity and dynamics of coexisting mutations have been shown to alter the prognosis and treatment response in patients with MDS. Often in the process of clonal evolution, various initial hits are preferentially followed by a specific spectrum of...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221211200308&amp;v=2.17.9"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221210200648&amp;v=2.17.9"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221209195756&amp;v=2.17.9"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221201200047&amp;v=2.17.8"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Radiation therapy (RT) to the chest increases the patients' risk of cardiovascular disease (CVD). A complete understanding of the mechanisms by which RT induces CVD could lead to specific preventive, therapeutic approaches. It is becoming evident that both genotoxic chemotherapy agents and radiation induce mitochondrial dysfunction and cellular senescence. Notably, one of the common phenotypes observed in cancer survivors is accelerated senescence, and immunosenescence is closely related to both...]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Radiation therapy (RT) to the chest increases the patients' risk of cardiovascular disease (CVD). A complete understanding of the mechanisms by which RT induces CVD could lead to specific preventive, therapeutic approaches. It is becoming evident that both genotoxic chemotherapy agents and radiation induce mitochondrial dysfunction and cellular senescence. Notably, one of the common phenotypes observed in cancer survivors is accelerated senescence, and immunosenescence is closely related to both...]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Radiation therapy (RT) to the chest increases the patients' risk of cardiovascular disease (CVD). A complete understanding of the mechanisms by which RT induces CVD could lead to specific preventive, therapeutic approaches. It is becoming evident that both genotoxic chemotherapy agents and radiation induce mitochondrial dysfunction and cellular senescence. Notably, one of the common phenotypes observed in cancer survivors is accelerated senescence, and immunosenescence is closely related to both...]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Radiation therapy (RT) to the chest increases the patients' risk of cardiovascular disease (CVD). A complete understanding of the mechanisms by which RT induces CVD could lead to specific preventive, therapeutic approaches. It is becoming evident that both genotoxic chemotherapy agents and radiation induce mitochondrial dysfunction and cellular senescence. Notably, one of the common phenotypes observed in cancer survivors is accelerated senescence, and immunosenescence is closely related to both...]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Radiation therapy (RT) to the chest increases the patients' risk of cardiovascular disease (CVD). A complete understanding of the mechanisms by which RT induces CVD could lead to specific preventive, therapeutic approaches. It is becoming evident that both genotoxic chemotherapy agents and radiation induce mitochondrial dysfunction and cellular senescence. Notably, one of the common phenotypes observed in cancer survivors is accelerated senescence, and immunosenescence is closely related to both...]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Radiation therapy (RT) to the chest increases the patients' risk of cardiovascular disease (CVD). A complete understanding of the mechanisms by which RT induces CVD could lead to specific preventive, therapeutic approaches. It is becoming evident that both genotoxic chemotherapy agents and radiation induce mitochondrial dysfunction and cellular senescence. Notably, one of the common phenotypes observed in cancer survivors is accelerated senescence, and immunosenescence is closely related to both...]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radiation therapy induces immunosenescence mediated by p90RSK]]></title>
        <id>pubmed:36426217</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36426217/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Radiation therapy (RT) to the chest increases the patients' risk of cardiovascular disease (CVD). A complete understanding of the mechanisms by which RT induces CVD could lead to specific preventive, therapeutic approaches. It is becoming evident that both genotoxic chemotherapy agents and radiation induce mitochondrial dysfunction and cellular senescence. Notably, one of the common phenotypes observed in cancer survivors is accelerated senescence, and immunosenescence is closely related to both...]]></summary>
        <author>
            <name>Masaki Imanishi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and spatial characteristics of tumor evolution in a mouse model of oral squamous cell carcinoma]]></title>
        <id>pubmed:36424557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Functional analysis of structural variants in single cells using Strand-seq]]></title>
        <id>pubmed:36424487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hyobin Jeong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy]]></title>
        <id>pubmed:36423362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36423362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>C Pixberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and spatial characteristics of tumor evolution in a mouse model of oral squamous cell carcinoma]]></title>
        <id>pubmed:36424557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Functional analysis of structural variants in single cells using Strand-seq]]></title>
        <id>pubmed:36424487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hyobin Jeong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy]]></title>
        <id>pubmed:36423362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36423362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>C Pixberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and spatial characteristics of tumor evolution in a mouse model of oral squamous cell carcinoma]]></title>
        <id>pubmed:36424557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Functional analysis of structural variants in single cells using Strand-seq]]></title>
        <id>pubmed:36424487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hyobin Jeong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy]]></title>
        <id>pubmed:36423362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36423362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>C Pixberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and spatial characteristics of tumor evolution in a mouse model of oral squamous cell carcinoma]]></title>
        <id>pubmed:36424557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Functional analysis of structural variants in single cells using Strand-seq]]></title>
        <id>pubmed:36424487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hyobin Jeong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy]]></title>
        <id>pubmed:36423362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36423362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>C Pixberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and spatial characteristics of tumor evolution in a mouse model of oral squamous cell carcinoma]]></title>
        <id>pubmed:36424557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Functional analysis of structural variants in single cells using Strand-seq]]></title>
        <id>pubmed:36424487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hyobin Jeong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy]]></title>
        <id>pubmed:36423362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36423362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>C Pixberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and spatial characteristics of tumor evolution in a mouse model of oral squamous cell carcinoma]]></title>
        <id>pubmed:36424557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Functional analysis of structural variants in single cells using Strand-seq]]></title>
        <id>pubmed:36424487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Hyobin Jeong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy]]></title>
        <id>pubmed:36423362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36423362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>C Pixberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and spatial characteristics of tumor evolution in a mouse model of oral squamous cell carcinoma]]></title>
        <id>pubmed:36424557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221201200049&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Tumor heterogeneity is significant in primary tumor cells and disseminated tumor cells. OSCC cells probably disseminate to lymph nodes in the early stage of oral carcinogenesis. OSCC is characterized by polyclonal dissemination, and the evolutionary trajectory of DTCs is potentially dominated by the tumor microenvironment.]]></summary>
        <author>
            <name>Yong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Functional analysis of structural variants in single cells using Strand-seq]]></title>
        <id>pubmed:36424487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221201200049&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic structural variants (SVs) are widespread in cancer, but their impact on disease evolution is understudied due to a lack of methods to directly characterize their functional consequences. We present a computational method, scNOVA, which uses Strand-seq to perform haplotype-aware integration of SV discovery and molecular phenotyping in single cells by using nucleosome occupancy to infer gene expression as a readout. Application to leukemias and cell lines identifies local effects of...]]></summary>
        <author>
            <name>Hyobin Jeong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy]]></title>
        <id>pubmed:36423362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36423362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221201200049&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: While most precision oncology initiatives focus on metastatic disease, the presented concept offers the opportunity to empower novel therapy options for patients with high-risk early breast cancer in the post-neoadjuvant setting within a biomarker-driven trial and provides the basis to test the value of precision oncology in a curative setting with the overarching goal to increase cure rates.]]></summary>
        <author>
            <name>C Pixberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and spatial characteristics of tumor evolution in a mouse model of oral squamous cell carcinoma]]></title>
        <id>pubmed:36424557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Tumor heterogeneity is significant in primary tumor cells and disseminated tumor cells. OSCC cells probably disseminate to lymph nodes in the early stage of oral carcinogenesis. OSCC is characterized by polyclonal dissemination, and the evolutionary trajectory of DTCs is potentially dominated by the tumor microenvironment.]]></summary>
        <author>
            <name>Yong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Functional analysis of structural variants in single cells using Strand-seq]]></title>
        <id>pubmed:36424487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic structural variants (SVs) are widespread in cancer, but their impact on disease evolution is understudied due to a lack of methods to directly characterize their functional consequences. We present a computational method, scNOVA, which uses Strand-seq to perform haplotype-aware integration of SV discovery and molecular phenotyping in single cells by using nucleosome occupancy to infer gene expression as a readout. Application to leukemias and cell lines identifies local effects of...]]></summary>
        <author>
            <name>Hyobin Jeong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy]]></title>
        <id>pubmed:36423362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36423362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: While most precision oncology initiatives focus on metastatic disease, the presented concept offers the opportunity to empower novel therapy options for patients with high-risk early breast cancer in the post-neoadjuvant setting within a biomarker-driven trial and provides the basis to test the value of precision oncology in a curative setting with the overarching goal to increase cure rates.]]></summary>
        <author>
            <name>C Pixberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and spatial characteristics of tumor evolution in a mouse model of oral squamous cell carcinoma]]></title>
        <id>pubmed:36424557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Tumor heterogeneity is significant in primary tumor cells and disseminated tumor cells. OSCC cells probably disseminate to lymph nodes in the early stage of oral carcinogenesis. OSCC is characterized by polyclonal dissemination, and the evolutionary trajectory of DTCs is potentially dominated by the tumor microenvironment.]]></summary>
        <author>
            <name>Yong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Functional analysis of structural variants in single cells using Strand-seq]]></title>
        <id>pubmed:36424487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic structural variants (SVs) are widespread in cancer, but their impact on disease evolution is understudied due to a lack of methods to directly characterize their functional consequences. We present a computational method, scNOVA, which uses Strand-seq to perform haplotype-aware integration of SV discovery and molecular phenotyping in single cells by using nucleosome occupancy to infer gene expression as a readout. Application to leukemias and cell lines identifies local effects of...]]></summary>
        <author>
            <name>Hyobin Jeong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy]]></title>
        <id>pubmed:36423362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36423362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: While most precision oncology initiatives focus on metastatic disease, the presented concept offers the opportunity to empower novel therapy options for patients with high-risk early breast cancer in the post-neoadjuvant setting within a biomarker-driven trial and provides the basis to test the value of precision oncology in a curative setting with the overarching goal to increase cure rates.]]></summary>
        <author>
            <name>C Pixberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and spatial characteristics of tumor evolution in a mouse model of oral squamous cell carcinoma]]></title>
        <id>pubmed:36424557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Tumor heterogeneity is significant in primary tumor cells and disseminated tumor cells. OSCC cells probably disseminate to lymph nodes in the early stage of oral carcinogenesis. OSCC is characterized by polyclonal dissemination, and the evolutionary trajectory of DTCs is potentially dominated by the tumor microenvironment.]]></summary>
        <author>
            <name>Yong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Functional analysis of structural variants in single cells using Strand-seq]]></title>
        <id>pubmed:36424487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic structural variants (SVs) are widespread in cancer, but their impact on disease evolution is understudied due to a lack of methods to directly characterize their functional consequences. We present a computational method, scNOVA, which uses Strand-seq to perform haplotype-aware integration of SV discovery and molecular phenotyping in single cells by using nucleosome occupancy to infer gene expression as a readout. Application to leukemias and cell lines identifies local effects of...]]></summary>
        <author>
            <name>Hyobin Jeong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy]]></title>
        <id>pubmed:36423362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36423362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: While most precision oncology initiatives focus on metastatic disease, the presented concept offers the opportunity to empower novel therapy options for patients with high-risk early breast cancer in the post-neoadjuvant setting within a biomarker-driven trial and provides the basis to test the value of precision oncology in a curative setting with the overarching goal to increase cure rates.]]></summary>
        <author>
            <name>C Pixberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and spatial characteristics of tumor evolution in a mouse model of oral squamous cell carcinoma]]></title>
        <id>pubmed:36424557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Tumor heterogeneity is significant in primary tumor cells and disseminated tumor cells. OSCC cells probably disseminate to lymph nodes in the early stage of oral carcinogenesis. OSCC is characterized by polyclonal dissemination, and the evolutionary trajectory of DTCs is potentially dominated by the tumor microenvironment.]]></summary>
        <author>
            <name>Yong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Functional analysis of structural variants in single cells using Strand-seq]]></title>
        <id>pubmed:36424487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic structural variants (SVs) are widespread in cancer, but their impact on disease evolution is understudied due to a lack of methods to directly characterize their functional consequences. We present a computational method, scNOVA, which uses Strand-seq to perform haplotype-aware integration of SV discovery and molecular phenotyping in single cells by using nucleosome occupancy to infer gene expression as a readout. Application to leukemias and cell lines identifies local effects of...]]></summary>
        <author>
            <name>Hyobin Jeong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy]]></title>
        <id>pubmed:36423362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36423362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: While most precision oncology initiatives focus on metastatic disease, the presented concept offers the opportunity to empower novel therapy options for patients with high-risk early breast cancer in the post-neoadjuvant setting within a biomarker-driven trial and provides the basis to test the value of precision oncology in a curative setting with the overarching goal to increase cure rates.]]></summary>
        <author>
            <name>C Pixberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and spatial characteristics of tumor evolution in a mouse model of oral squamous cell carcinoma]]></title>
        <id>pubmed:36424557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Tumor heterogeneity is significant in primary tumor cells and disseminated tumor cells. OSCC cells probably disseminate to lymph nodes in the early stage of oral carcinogenesis. OSCC is characterized by polyclonal dissemination, and the evolutionary trajectory of DTCs is potentially dominated by the tumor microenvironment.]]></summary>
        <author>
            <name>Yong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Functional analysis of structural variants in single cells using Strand-seq]]></title>
        <id>pubmed:36424487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic structural variants (SVs) are widespread in cancer, but their impact on disease evolution is understudied due to a lack of methods to directly characterize their functional consequences. We present a computational method, scNOVA, which uses Strand-seq to perform haplotype-aware integration of SV discovery and molecular phenotyping in single cells by using nucleosome occupancy to infer gene expression as a readout. Application to leukemias and cell lines identifies local effects of...]]></summary>
        <author>
            <name>Hyobin Jeong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy]]></title>
        <id>pubmed:36423362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36423362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: While most precision oncology initiatives focus on metastatic disease, the presented concept offers the opportunity to empower novel therapy options for patients with high-risk early breast cancer in the post-neoadjuvant setting within a biomarker-driven trial and provides the basis to test the value of precision oncology in a curative setting with the overarching goal to increase cure rates.]]></summary>
        <author>
            <name>C Pixberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and spatial characteristics of tumor evolution in a mouse model of oral squamous cell carcinoma]]></title>
        <id>pubmed:36424557</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424557/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Tumor heterogeneity is significant in primary tumor cells and disseminated tumor cells. OSCC cells probably disseminate to lymph nodes in the early stage of oral carcinogenesis. OSCC is characterized by polyclonal dissemination, and the evolutionary trajectory of DTCs is potentially dominated by the tumor microenvironment.]]></summary>
        <author>
            <name>Yong Cao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Functional analysis of structural variants in single cells using Strand-seq]]></title>
        <id>pubmed:36424487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36424487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic structural variants (SVs) are widespread in cancer, but their impact on disease evolution is understudied due to a lack of methods to directly characterize their functional consequences. We present a computational method, scNOVA, which uses Strand-seq to perform haplotype-aware integration of SV discovery and molecular phenotyping in single cells by using nucleosome occupancy to infer gene expression as a readout. Application to leukemias and cell lines identifies local effects of...]]></summary>
        <author>
            <name>Hyobin Jeong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy]]></title>
        <id>pubmed:36423362</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36423362/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: While most precision oncology initiatives focus on metastatic disease, the presented concept offers the opportunity to empower novel therapy options for patients with high-risk early breast cancer in the post-neoadjuvant setting within a biomarker-driven trial and provides the basis to test the value of precision oncology in a curative setting with the overarching goal to increase cure rates.]]></summary>
        <author>
            <name>C Pixberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for clonal hematopoiesis of indeterminate potential and mosaic chromosomal alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for clonal hematopoiesis of indeterminate potential and mosaic chromosomal alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk factors for clonal hematopoiesis of indeterminate potential and mosaic chromosomal alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential and Mosaic Chromosomal Alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential and Mosaic Chromosomal Alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential and Mosaic Chromosomal Alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential and Mosaic Chromosomal Alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential and Mosaic Chromosomal Alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221201200047&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) of the autosomes, X, and Y chromosomes are aging-related somatic mutations detectable in peripheral blood. The presence of these acquired mutations predisposes otherwise healthy adults to increased risk of several chronic aging-related conditions including hematologic cancers, atherosclerotic cardiovascular diseases, other inflammatory conditions, and mortality. While the public health impact and...]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential and Mosaic Chromosomal Alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) of the autosomes, X, and Y chromosomes are aging-related somatic mutations detectable in peripheral blood. The presence of these acquired mutations predisposes otherwise healthy adults to increased risk of several chronic aging-related conditions including hematologic cancers, atherosclerotic cardiovascular diseases, other inflammatory conditions, and mortality. While the public health impact and...]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential and Mosaic Chromosomal Alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) of the autosomes, X, and Y chromosomes are aging-related somatic mutations detectable in peripheral blood. The presence of these acquired mutations predisposes otherwise healthy adults to increased risk of several chronic aging-related conditions including hematologic cancers, atherosclerotic cardiovascular diseases, other inflammatory conditions, and mortality. While the public health impact and...]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential and Mosaic Chromosomal Alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) of the autosomes, X, and Y chromosomes are aging-related somatic mutations detectable in peripheral blood. The presence of these acquired mutations predisposes otherwise healthy adults to increased risk of several chronic aging-related conditions including hematologic cancers, atherosclerotic cardiovascular diseases, other inflammatory conditions, and mortality. While the public health impact and...]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential and Mosaic Chromosomal Alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) of the autosomes, X, and Y chromosomes are aging-related somatic mutations detectable in peripheral blood. The presence of these acquired mutations predisposes otherwise healthy adults to increased risk of several chronic aging-related conditions including hematologic cancers, atherosclerotic cardiovascular diseases, other inflammatory conditions, and mortality. While the public health impact and...]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential and Mosaic Chromosomal Alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) of the autosomes, X, and Y chromosomes are aging-related somatic mutations detectable in peripheral blood. The presence of these acquired mutations predisposes otherwise healthy adults to increased risk of several chronic aging-related conditions including hematologic cancers, atherosclerotic cardiovascular diseases, other inflammatory conditions, and mortality. While the public health impact and...]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential and Mosaic Chromosomal Alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) of the autosomes, X, and Y chromosomes are aging-related somatic mutations detectable in peripheral blood. The presence of these acquired mutations predisposes otherwise healthy adults to increased risk of several chronic aging-related conditions including hematologic cancers, atherosclerotic cardiovascular diseases, other inflammatory conditions, and mortality. While the public health impact and...]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential and Mosaic Chromosomal Alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) of the autosomes, X, and Y chromosomes are aging-related somatic mutations detectable in peripheral blood. The presence of these acquired mutations predisposes otherwise healthy adults to increased risk of several chronic aging-related conditions including hematologic cancers, atherosclerotic cardiovascular diseases, other inflammatory conditions, and mortality. While the public health impact and...]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential and Mosaic Chromosomal Alterations]]></title>
        <id>pubmed:36414227</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414227/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) of the autosomes, X, and Y chromosomes are aging-related somatic mutations detectable in peripheral blood. The presence of these acquired mutations predisposes otherwise healthy adults to increased risk of several chronic aging-related conditions including hematologic cancers, atherosclerotic cardiovascular diseases, other inflammatory conditions, and mortality. While the public health impact and...]]></summary>
        <author>
            <name>Yasminka A Jakubek</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Plasma cell neoplasms and related entities-evolution in diagnosis and classification]]></title>
        <id>pubmed:36414803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Falko Fend</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Plasma cell neoplasms and related entities-evolution in diagnosis and classification]]></title>
        <id>pubmed:36414803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Falko Fend</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report]]></title>
        <id>pubmed:36412315</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36412315/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Rupa C Dalvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Plasma cell neoplasms and related entities-evolution in diagnosis and classification]]></title>
        <id>pubmed:36414803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Falko Fend</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report]]></title>
        <id>pubmed:36412315</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36412315/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Rupa C Dalvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Plasma cell neoplasms and related entities-evolution in diagnosis and classification]]></title>
        <id>pubmed:36414803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Falko Fend</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report]]></title>
        <id>pubmed:36412315</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36412315/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Rupa C Dalvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Plasma cell neoplasms and related entities-evolution in diagnosis and classification]]></title>
        <id>pubmed:36414803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Falko Fend</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report]]></title>
        <id>pubmed:36412315</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36412315/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Rupa C Dalvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Plasma cell neoplasms and related entities-evolution in diagnosis and classification]]></title>
        <id>pubmed:36414803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221201200049&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma cell neoplasms including multiple myeloma (MM) and related terminally differentiated B-cell neoplasms are characterized by secretion of monoclonal immunoglobulin and stepwise development from a preneoplastic clonal B and/or plasma cell proliferation called monoclonal gammopathy of undetermined significance (MGUS). Diagnosis of these disorders requires integration of clinical, laboratory, and morphological features. While their classification mostly remains unchanged compared to the...]]></summary>
        <author>
            <name>Falko Fend</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report]]></title>
        <id>pubmed:36412315</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36412315/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221201200049&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute promyelocytic leukemia (APL) is a type of acute myeloid leukemia (AML) characterized by the presence of t(15;17)(q22;q21) translocation leading to fusion between PML and RARa gene. Treatment combining all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has dramatically improved the prognosis of APL. We report a rare finding of primary clone of t(15;17) followed by a sequential clonal evolution of additional derivative chromosome 6 formation by a two hit mechanism. Our case showed a...]]></summary>
        <author>
            <name>Rupa C Dalvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Plasma cell neoplasms and related entities-evolution in diagnosis and classification]]></title>
        <id>pubmed:36414803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma cell neoplasms including multiple myeloma (MM) and related terminally differentiated B-cell neoplasms are characterized by secretion of monoclonal immunoglobulin and stepwise development from a preneoplastic clonal B and/or plasma cell proliferation called monoclonal gammopathy of undetermined significance (MGUS). Diagnosis of these disorders requires integration of clinical, laboratory, and morphological features. While their classification mostly remains unchanged compared to the...]]></summary>
        <author>
            <name>Falko Fend</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report]]></title>
        <id>pubmed:36412315</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36412315/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute promyelocytic leukemia (APL) is a type of acute myeloid leukemia (AML) characterized by the presence of t(15;17)(q22;q21) translocation leading to fusion between PML and RARa gene. Treatment combining all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has dramatically improved the prognosis of APL. We report a rare finding of primary clone of t(15;17) followed by a sequential clonal evolution of additional derivative chromosome 6 formation by a two hit mechanism. Our case showed a...]]></summary>
        <author>
            <name>Rupa C Dalvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Plasma cell neoplasms and related entities-evolution in diagnosis and classification]]></title>
        <id>pubmed:36414803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma cell neoplasms including multiple myeloma (MM) and related terminally differentiated B-cell neoplasms are characterized by secretion of monoclonal immunoglobulin and stepwise development from a preneoplastic clonal B and/or plasma cell proliferation called monoclonal gammopathy of undetermined significance (MGUS). Diagnosis of these disorders requires integration of clinical, laboratory, and morphological features. While their classification mostly remains unchanged compared to the...]]></summary>
        <author>
            <name>Falko Fend</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report]]></title>
        <id>pubmed:36412315</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36412315/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute promyelocytic leukemia (APL) is a type of acute myeloid leukemia (AML) characterized by the presence of t(15;17)(q22;q21) translocation leading to fusion between PML and RARa gene. Treatment combining all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has dramatically improved the prognosis of APL. We report a rare finding of primary clone of t(15;17) followed by a sequential clonal evolution of additional derivative chromosome 6 formation by a two hit mechanism. Our case showed a...]]></summary>
        <author>
            <name>Rupa C Dalvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Plasma cell neoplasms and related entities-evolution in diagnosis and classification]]></title>
        <id>pubmed:36414803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma cell neoplasms including multiple myeloma (MM) and related terminally differentiated B-cell neoplasms are characterized by secretion of monoclonal immunoglobulin and stepwise development from a preneoplastic clonal B and/or plasma cell proliferation called monoclonal gammopathy of undetermined significance (MGUS). Diagnosis of these disorders requires integration of clinical, laboratory, and morphological features. While their classification mostly remains unchanged compared to the...]]></summary>
        <author>
            <name>Falko Fend</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report]]></title>
        <id>pubmed:36412315</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36412315/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute promyelocytic leukemia (APL) is a type of acute myeloid leukemia (AML) characterized by the presence of t(15;17)(q22;q21) translocation leading to fusion between PML and RARa gene. Treatment combining all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has dramatically improved the prognosis of APL. We report a rare finding of primary clone of t(15;17) followed by a sequential clonal evolution of additional derivative chromosome 6 formation by a two hit mechanism. Our case showed a...]]></summary>
        <author>
            <name>Rupa C Dalvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Plasma cell neoplasms and related entities-evolution in diagnosis and classification]]></title>
        <id>pubmed:36414803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma cell neoplasms including multiple myeloma (MM) and related terminally differentiated B-cell neoplasms are characterized by secretion of monoclonal immunoglobulin and stepwise development from a preneoplastic clonal B and/or plasma cell proliferation called monoclonal gammopathy of undetermined significance (MGUS). Diagnosis of these disorders requires integration of clinical, laboratory, and morphological features. While their classification mostly remains unchanged compared to the...]]></summary>
        <author>
            <name>Falko Fend</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report]]></title>
        <id>pubmed:36412315</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36412315/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute promyelocytic leukemia (APL) is a type of acute myeloid leukemia (AML) characterized by the presence of t(15;17)(q22;q21) translocation leading to fusion between PML and RARa gene. Treatment combining all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has dramatically improved the prognosis of APL. We report a rare finding of primary clone of t(15;17) followed by a sequential clonal evolution of additional derivative chromosome 6 formation by a two hit mechanism. Our case showed a...]]></summary>
        <author>
            <name>Rupa C Dalvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Plasma cell neoplasms and related entities-evolution in diagnosis and classification]]></title>
        <id>pubmed:36414803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma cell neoplasms including multiple myeloma (MM) and related terminally differentiated B-cell neoplasms are characterized by secretion of monoclonal immunoglobulin and stepwise development from a preneoplastic clonal B and/or plasma cell proliferation called monoclonal gammopathy of undetermined significance (MGUS). Diagnosis of these disorders requires integration of clinical, laboratory, and morphological features. While their classification mostly remains unchanged compared to the...]]></summary>
        <author>
            <name>Falko Fend</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report]]></title>
        <id>pubmed:36412315</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36412315/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute promyelocytic leukemia (APL) is a type of acute myeloid leukemia (AML) characterized by the presence of t(15;17)(q22;q21) translocation leading to fusion between PML and RARa gene. Treatment combining all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has dramatically improved the prognosis of APL. We report a rare finding of primary clone of t(15;17) followed by a sequential clonal evolution of additional derivative chromosome 6 formation by a two hit mechanism. Our case showed a...]]></summary>
        <author>
            <name>Rupa C Dalvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Plasma cell neoplasms and related entities-evolution in diagnosis and classification]]></title>
        <id>pubmed:36414803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma cell neoplasms including multiple myeloma (MM) and related terminally differentiated B-cell neoplasms are characterized by secretion of monoclonal immunoglobulin and stepwise development from a preneoplastic clonal B and/or plasma cell proliferation called monoclonal gammopathy of undetermined significance (MGUS). Diagnosis of these disorders requires integration of clinical, laboratory, and morphological features. While their classification mostly remains unchanged compared to the...]]></summary>
        <author>
            <name>Falko Fend</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report]]></title>
        <id>pubmed:36412315</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36412315/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute promyelocytic leukemia (APL) is a type of acute myeloid leukemia (AML) characterized by the presence of t(15;17)(q22;q21) translocation leading to fusion between PML and RARa gene. Treatment combining all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has dramatically improved the prognosis of APL. We report a rare finding of primary clone of t(15;17) followed by a sequential clonal evolution of additional derivative chromosome 6 formation by a two hit mechanism. Our case showed a...]]></summary>
        <author>
            <name>Rupa C Dalvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Plasma cell neoplasms and related entities-evolution in diagnosis and classification]]></title>
        <id>pubmed:36414803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma cell neoplasms including multiple myeloma (MM) and related terminally differentiated B-cell neoplasms are characterized by secretion of monoclonal immunoglobulin and stepwise development from a preneoplastic clonal B and/or plasma cell proliferation called monoclonal gammopathy of undetermined significance (MGUS). Diagnosis of these disorders requires integration of clinical, laboratory, and morphological features. While their classification mostly remains unchanged compared to the...]]></summary>
        <author>
            <name>Falko Fend</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report]]></title>
        <id>pubmed:36412315</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36412315/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute promyelocytic leukemia (APL) is a type of acute myeloid leukemia (AML) characterized by the presence of t(15;17)(q22;q21) translocation leading to fusion between PML and RARa gene. Treatment combining all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has dramatically improved the prognosis of APL. We report a rare finding of primary clone of t(15;17) followed by a sequential clonal evolution of additional derivative chromosome 6 formation by a two hit mechanism. Our case showed a...]]></summary>
        <author>
            <name>Rupa C Dalvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Plasma cell neoplasms and related entities-evolution in diagnosis and classification]]></title>
        <id>pubmed:36414803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36414803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Plasma cell neoplasms including multiple myeloma (MM) and related terminally differentiated B-cell neoplasms are characterized by secretion of monoclonal immunoglobulin and stepwise development from a preneoplastic clonal B and/or plasma cell proliferation called monoclonal gammopathy of undetermined significance (MGUS). Diagnosis of these disorders requires integration of clinical, laboratory, and morphological features. While their classification mostly remains unchanged compared to the...]]></summary>
        <author>
            <name>Falko Fend</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report]]></title>
        <id>pubmed:36412315</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36412315/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute promyelocytic leukemia (APL) is a type of acute myeloid leukemia (AML) characterized by the presence of t(15;17)(q22;q21) translocation leading to fusion between PML and RARa gene. Treatment combining all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has dramatically improved the prognosis of APL. We report a rare finding of primary clone of t(15;17) followed by a sequential clonal evolution of additional derivative chromosome 6 formation by a two hit mechanism. Our case showed a...]]></summary>
        <author>
            <name>Rupa C Dalvi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2]]></title>
        <id>pubmed:36405946</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36405946/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Dana Narvez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2]]></title>
        <id>pubmed:36405946</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36405946/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Dana Narvez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2]]></title>
        <id>pubmed:36405946</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36405946/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Dana Narvez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2]]></title>
        <id>pubmed:36405946</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36405946/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221201200049&amp;v=2.17.8"/>
        <updated>2022-11-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Undoubtedly, more information regarding the cost effectiveness of NGS is needed to develop adequate reimbursement policies for this technology. It should be highlighted that the generalisation of MTBs and the implementation of molecular screening programmes are greatly needed in our region to gain more knowledge of somatic mutations implicated in the Hispanic and Latin-American population with BC diagnosis. Recently presented results of randomised studies may support the evaluation...]]></summary>
        <author>
            <name>Dana Narvez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2]]></title>
        <id>pubmed:36405946</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36405946/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Undoubtedly, more information regarding the cost effectiveness of NGS is needed to develop adequate reimbursement policies for this technology. It should be highlighted that the generalisation of MTBs and the implementation of molecular screening programmes are greatly needed in our region to gain more knowledge of somatic mutations implicated in the Hispanic and Latin-American population with BC diagnosis. Recently presented results of randomised studies may support the evaluation...]]></summary>
        <author>
            <name>Dana Narvez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2]]></title>
        <id>pubmed:36405946</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36405946/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Undoubtedly, more information regarding the cost effectiveness of NGS is needed to develop adequate reimbursement policies for this technology. It should be highlighted that the generalisation of MTBs and the implementation of molecular screening programmes are greatly needed in our region to gain more knowledge of somatic mutations implicated in the Hispanic and Latin-American population with BC diagnosis. Recently presented results of randomised studies may support the evaluation...]]></summary>
        <author>
            <name>Dana Narvez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2]]></title>
        <id>pubmed:36405946</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36405946/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Undoubtedly, more information regarding the cost effectiveness of NGS is needed to develop adequate reimbursement policies for this technology. It should be highlighted that the generalisation of MTBs and the implementation of molecular screening programmes are greatly needed in our region to gain more knowledge of somatic mutations implicated in the Hispanic and Latin-American population with BC diagnosis. Recently presented results of randomised studies may support the evaluation...]]></summary>
        <author>
            <name>Dana Narvez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2]]></title>
        <id>pubmed:36405946</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36405946/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Undoubtedly, more information regarding the cost effectiveness of NGS is needed to develop adequate reimbursement policies for this technology. It should be highlighted that the generalisation of MTBs and the implementation of molecular screening programmes are greatly needed in our region to gain more knowledge of somatic mutations implicated in the Hispanic and Latin-American population with BC diagnosis. Recently presented results of randomised studies may support the evaluation...]]></summary>
        <author>
            <name>Dana Narvez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2]]></title>
        <id>pubmed:36405946</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36405946/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Undoubtedly, more information regarding the cost effectiveness of NGS is needed to develop adequate reimbursement policies for this technology. It should be highlighted that the generalisation of MTBs and the implementation of molecular screening programmes are greatly needed in our region to gain more knowledge of somatic mutations implicated in the Hispanic and Latin-American population with BC diagnosis. Recently presented results of randomised studies may support the evaluation...]]></summary>
        <author>
            <name>Dana Narvez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2]]></title>
        <id>pubmed:36405946</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36405946/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Undoubtedly, more information regarding the cost effectiveness of NGS is needed to develop adequate reimbursement policies for this technology. It should be highlighted that the generalisation of MTBs and the implementation of molecular screening programmes are greatly needed in our region to gain more knowledge of somatic mutations implicated in the Hispanic and Latin-American population with BC diagnosis. Recently presented results of randomised studies may support the evaluation...]]></summary>
        <author>
            <name>Dana Narvez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2]]></title>
        <id>pubmed:36405946</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36405946/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Undoubtedly, more information regarding the cost effectiveness of NGS is needed to develop adequate reimbursement policies for this technology. It should be highlighted that the generalisation of MTBs and the implementation of molecular screening programmes are greatly needed in our region to gain more knowledge of somatic mutations implicated in the Hispanic and Latin-American population with BC diagnosis. Recently presented results of randomised studies may support the evaluation...]]></summary>
        <author>
            <name>Dana Narvez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2]]></title>
        <id>pubmed:36405946</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36405946/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Undoubtedly, more information regarding the cost effectiveness of NGS is needed to develop adequate reimbursement policies for this technology. It should be highlighted that the generalisation of MTBs and the implementation of molecular screening programmes are greatly needed in our region to gain more knowledge of somatic mutations implicated in the Hispanic and Latin-American population with BC diagnosis. Recently presented results of randomised studies may support the evaluation...]]></summary>
        <author>
            <name>Dana Narvez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2]]></title>
        <id>pubmed:36405946</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36405946/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Undoubtedly, more information regarding the cost effectiveness of NGS is needed to develop adequate reimbursement policies for this technology. It should be highlighted that the generalisation of MTBs and the implementation of molecular screening programmes are greatly needed in our region to gain more knowledge of somatic mutations implicated in the Hispanic and Latin-American population with BC diagnosis. Recently presented results of randomised studies may support the evaluation...]]></summary>
        <author>
            <name>Dana Narvez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2]]></title>
        <id>pubmed:36405946</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36405946/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Undoubtedly, more information regarding the cost effectiveness of NGS is needed to develop adequate reimbursement policies for this technology. It should be highlighted that the generalisation of MTBs and the implementation of molecular screening programmes are greatly needed in our region to gain more knowledge of somatic mutations implicated in the Hispanic and Latin-American population with BC diagnosis. Recently presented results of randomised studies may support the evaluation...]]></summary>
        <author>
            <name>Dana Narvez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221201200047&amp;v=2.17.8"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue stem cells maintain themselves through self-renewal while constantly supplying differentiating cells. Two distinct models have been proposed as mechanisms of stem cell homeostasis. According to the classical model, there is hierarchy among stem cells, and master stem cells produce stem cells by asymmetric division; whereas, according to the recent model, stem cells are equipotent and neutrally compete. However, the mechanism remains controversial in several tissues and species. Here, we...]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue stem cells maintain themselves through self-renewal while constantly supplying differentiating cells. Two distinct models have been proposed as mechanisms of stem cell homeostasis. According to the classical model, there is hierarchy among stem cells, and master stem cells produce stem cells by asymmetric division; whereas, according to the recent model, stem cells are equipotent and neutrally compete. However, the mechanism remains controversial in several tissues and species. Here, we...]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue stem cells maintain themselves through self-renewal while constantly supplying differentiating cells. Two distinct models have been proposed as mechanisms of stem cell homeostasis. According to the classical model, there is hierarchy among stem cells, and master stem cells produce stem cells by asymmetric division; whereas, according to the recent model, stem cells are equipotent and neutrally compete. However, the mechanism remains controversial in several tissues and species. Here, we...]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue stem cells maintain themselves through self-renewal while constantly supplying differentiating cells. Two distinct models have been proposed as mechanisms of stem cell homeostasis. According to the classical model, there is hierarchy among stem cells, and master stem cells produce stem cells by asymmetric division; whereas, according to the recent model, stem cells are equipotent and neutrally compete. However, the mechanism remains controversial in several tissues and species. Here, we...]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue stem cells maintain themselves through self-renewal while constantly supplying differentiating cells. Two distinct models have been proposed as mechanisms of stem cell homeostasis. According to the classical model, there is hierarchy among stem cells, and master stem cells produce stem cells by asymmetric division; whereas, according to the recent model, stem cells are equipotent and neutrally compete. However, the mechanism remains controversial in several tissues and species. Here, we...]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue stem cells maintain themselves through self-renewal while constantly supplying differentiating cells. Two distinct models have been proposed as mechanisms of stem cell homeostasis. According to the classical model, there is hierarchy among stem cells, and master stem cells produce stem cells by asymmetric division; whereas, according to the recent model, stem cells are equipotent and neutrally compete. However, the mechanism remains controversial in several tissues and species. Here, we...]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue stem cells maintain themselves through self-renewal while constantly supplying differentiating cells. Two distinct models have been proposed as mechanisms of stem cell homeostasis. According to the classical model, there is hierarchy among stem cells, and master stem cells produce stem cells by asymmetric division; whereas, according to the recent model, stem cells are equipotent and neutrally compete. However, the mechanism remains controversial in several tissues and species. Here, we...]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue stem cells maintain themselves through self-renewal while constantly supplying differentiating cells. Two distinct models have been proposed as mechanisms of stem cell homeostasis. According to the classical model, there is hierarchy among stem cells, and master stem cells produce stem cells by asymmetric division; whereas, according to the recent model, stem cells are equipotent and neutrally compete. However, the mechanism remains controversial in several tissues and species. Here, we...]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue stem cells maintain themselves through self-renewal while constantly supplying differentiating cells. Two distinct models have been proposed as mechanisms of stem cell homeostasis. According to the classical model, there is hierarchy among stem cells, and master stem cells produce stem cells by asymmetric division; whereas, according to the recent model, stem cells are equipotent and neutrally compete. However, the mechanism remains controversial in several tissues and species. Here, we...]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue stem cells maintain themselves through self-renewal while constantly supplying differentiating cells. Two distinct models have been proposed as mechanisms of stem cell homeostasis. According to the classical model, there is hierarchy among stem cells, and master stem cells produce stem cells by asymmetric division; whereas, according to the recent model, stem cells are equipotent and neutrally compete. However, the mechanism remains controversial in several tissues and species. Here, we...]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue stem cells maintain themselves through self-renewal while constantly supplying differentiating cells. Two distinct models have been proposed as mechanisms of stem cell homeostasis. According to the classical model, there is hierarchy among stem cells, and master stem cells produce stem cells by asymmetric division; whereas, according to the recent model, stem cells are equipotent and neutrally compete. However, the mechanism remains controversial in several tissues and species. Here, we...]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue stem cells maintain themselves through self-renewal while constantly supplying differentiating cells. Two distinct models have been proposed as mechanisms of stem cell homeostasis. According to the classical model, there is hierarchy among stem cells, and master stem cells produce stem cells by asymmetric division; whereas, according to the recent model, stem cells are equipotent and neutrally compete. However, the mechanism remains controversial in several tissues and species. Here, we...]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell homeostasis regulated by hierarchy and neutral competition]]></title>
        <id>pubmed:36400843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36400843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221119201545&amp;v=2.17.8"/>
        <updated>2022-11-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue stem cells maintain themselves through self-renewal while constantly supplying differentiating cells. Two distinct models have been proposed as mechanisms of stem cell homeostasis. According to the classical model, there is hierarchy among stem cells, and master stem cells produce stem cells by asymmetric division; whereas, according to the recent model, stem cells are equipotent and neutrally compete. However, the mechanism remains controversial in several tissues and species. Here, we...]]></summary>
        <author>
            <name>Asahi Nakamuta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221208200156&amp;v=2.17.9"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221201200047&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome and acute myeloid leukemia are heterogeneous myeloid neoplasms which arise from the accumulation of mutations in a myeloid stem cell or progenitor that confer survival or growth advantages. These disease processes are formally differentiated by clinical, laboratory, and morphological presentations, especially with regard to the preponderance of blasts in the peripheral blood or bone marrow (AML); however, they are closely associated through their shared lineage as well...]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221201200047&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome and acute myeloid leukemia are heterogeneous myeloid neoplasms which arise from the accumulation of mutations in a myeloid stem cell or progenitor that confer survival or growth advantages. These disease processes are formally differentiated by clinical, laboratory, and morphological presentations, especially with regard to the preponderance of blasts in the peripheral blood or bone marrow (AML); however, they are closely associated through their shared lineage as well...]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome and acute myeloid leukemia are heterogeneous myeloid neoplasms which arise from the accumulation of mutations in a myeloid stem cell or progenitor that confer survival or growth advantages. These disease processes are formally differentiated by clinical, laboratory, and morphological presentations, especially with regard to the preponderance of blasts in the peripheral blood or bone marrow (AML); however, they are closely associated through their shared lineage as well...]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome and acute myeloid leukemia are heterogeneous myeloid neoplasms which arise from the accumulation of mutations in a myeloid stem cell or progenitor that confer survival or growth advantages. These disease processes are formally differentiated by clinical, laboratory, and morphological presentations, especially with regard to the preponderance of blasts in the peripheral blood or bone marrow (AML); however, they are closely associated through their shared lineage as well...]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome and acute myeloid leukemia are heterogeneous myeloid neoplasms which arise from the accumulation of mutations in a myeloid stem cell or progenitor that confer survival or growth advantages. These disease processes are formally differentiated by clinical, laboratory, and morphological presentations, especially with regard to the preponderance of blasts in the peripheral blood or bone marrow (AML); however, they are closely associated through their shared lineage as well...]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome and acute myeloid leukemia are heterogeneous myeloid neoplasms which arise from the accumulation of mutations in a myeloid stem cell or progenitor that confer survival or growth advantages. These disease processes are formally differentiated by clinical, laboratory, and morphological presentations, especially with regard to the preponderance of blasts in the peripheral blood or bone marrow (AML); however, they are closely associated through their shared lineage as well...]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome and acute myeloid leukemia are heterogeneous myeloid neoplasms which arise from the accumulation of mutations in a myeloid stem cell or progenitor that confer survival or growth advantages. These disease processes are formally differentiated by clinical, laboratory, and morphological presentations, especially with regard to the preponderance of blasts in the peripheral blood or bone marrow (AML); however, they are closely associated through their shared lineage as well...]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome and acute myeloid leukemia are heterogeneous myeloid neoplasms which arise from the accumulation of mutations in a myeloid stem cell or progenitor that confer survival or growth advantages. These disease processes are formally differentiated by clinical, laboratory, and morphological presentations, especially with regard to the preponderance of blasts in the peripheral blood or bone marrow (AML); however, they are closely associated through their shared lineage as well...]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome and acute myeloid leukemia are heterogeneous myeloid neoplasms which arise from the accumulation of mutations in a myeloid stem cell or progenitor that confer survival or growth advantages. These disease processes are formally differentiated by clinical, laboratory, and morphological presentations, especially with regard to the preponderance of blasts in the peripheral blood or bone marrow (AML); however, they are closely associated through their shared lineage as well...]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome and acute myeloid leukemia are heterogeneous myeloid neoplasms which arise from the accumulation of mutations in a myeloid stem cell or progenitor that confer survival or growth advantages. These disease processes are formally differentiated by clinical, laboratory, and morphological presentations, especially with regard to the preponderance of blasts in the peripheral blood or bone marrow (AML); however, they are closely associated through their shared lineage as well...]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome and acute myeloid leukemia are heterogeneous myeloid neoplasms which arise from the accumulation of mutations in a myeloid stem cell or progenitor that confer survival or growth advantages. These disease processes are formally differentiated by clinical, laboratory, and morphological presentations, especially with regard to the preponderance of blasts in the peripheral blood or bone marrow (AML); however, they are closely associated through their shared lineage as well...]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome and acute myeloid leukemia are heterogeneous myeloid neoplasms which arise from the accumulation of mutations in a myeloid stem cell or progenitor that confer survival or growth advantages. These disease processes are formally differentiated by clinical, laboratory, and morphological presentations, especially with regard to the preponderance of blasts in the peripheral blood or bone marrow (AML); however, they are closely associated through their shared lineage as well...]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221119201545&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome and acute myeloid leukemia are heterogeneous myeloid neoplasms which arise from the accumulation of mutations in a myeloid stem cell or progenitor that confer survival or growth advantages. These disease processes are formally differentiated by clinical, laboratory, and morphological presentations, especially with regard to the preponderance of blasts in the peripheral blood or bone marrow (AML); however, they are closely associated through their shared lineage as well...]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221119201545&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome and acute myeloid leukemia are heterogeneous myeloid neoplasms which arise from the accumulation of mutations in a myeloid stem cell or progenitor that confer survival or growth advantages. These disease processes are formally differentiated by clinical, laboratory, and morphological presentations, especially with regard to the preponderance of blasts in the peripheral blood or bone marrow (AML); however, they are closely associated through their shared lineage as well...]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia]]></title>
        <id>pubmed:36387170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36387170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221117201524&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome and acute myeloid leukemia are heterogeneous myeloid neoplasms which arise from the accumulation of mutations in a myeloid stem cell or progenitor that confer survival or growth advantages. These disease processes are formally differentiated by clinical, laboratory, and morphological presentations, especially with regard to the preponderance of blasts in the peripheral blood or bone marrow (AML); however, they are closely associated through their shared lineage as well...]]></summary>
        <author>
            <name>Alexander J Ambinder</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm]]></title>
        <id>pubmed:36384248</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36384248/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221117201524&amp;v=2.17.8"/>
        <updated>2022-11-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Not available.]]></summary>
        <author>
            <name>Ying Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221207195957&amp;v=2.17.9"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221206200240&amp;v=2.17.9"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221205195947&amp;v=2.17.9"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221201200047&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221119201545&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221117201524&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- &gt;clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221116201100&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Aging drives Tet2+/- &gt;clonal hematopoiesis via IL-1 signaling]]></title>
        <id>pubmed:36379023</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379023/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221115201214&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis (ARCH), is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells over 4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating...]]></summary>
        <author>
            <name>Francisco Caiado</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221204195949&amp;v=2.17.9"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221203200131&amp;v=2.17.9"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221202195829&amp;v=2.17.9"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[No abstract]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221201200049&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[A recent Nature study delineates a stepwise genomic evolution during pancreatic cancer development, employing an engineered mutant Kras and heterozygous Trp53 mouse model that identifies cells undergoing Trp53 loss of heterozygosity (LOH). Genetic progression post-Trp53 LOH involves clonal deletions, then genome doubling and subsequent accumulation of subclonal gains and amplifications.]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221201200049&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[A recent Nature study delineates a stepwise genomic evolution during pancreatic cancer development, employing an engineered mutant Kras and heterozygous Trp53 mouse model that identifies cells undergoing Trp53 loss of heterozygosity (LOH). Genetic progression post-Trp53 LOH involves clonal deletions, then genome doubling and subsequent accumulation of subclonal gains and amplifications.]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[A recent Nature study delineates a stepwise genomic evolution during pancreatic cancer development, employing an engineered mutant Kras and heterozygous Trp53 mouse model that identifies cells undergoing Trp53 loss of heterozygosity (LOH). Genetic progression post-Trp53 LOH involves clonal deletions, then genome doubling and subsequent accumulation of subclonal gains and amplifications.]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[A recent Nature study delineates a stepwise genomic evolution during pancreatic cancer development, employing an engineered mutant Kras and heterozygous Trp53 mouse model that identifies cells undergoing Trp53 loss of heterozygosity (LOH). Genetic progression post-Trp53 LOH involves clonal deletions, then genome doubling and subsequent accumulation of subclonal gains and amplifications.]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[A recent Nature study delineates a stepwise genomic evolution during pancreatic cancer development, employing an engineered mutant Kras and heterozygous Trp53 mouse model that identifies cells undergoing Trp53 loss of heterozygosity (LOH). Genetic progression post-Trp53 LOH involves clonal deletions, then genome doubling and subsequent accumulation of subclonal gains and amplifications.]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[A recent Nature study delineates a stepwise genomic evolution during pancreatic cancer development, employing an engineered mutant Kras and heterozygous Trp53 mouse model that identifies cells undergoing Trp53 loss of heterozygosity (LOH). Genetic progression post-Trp53 LOH involves clonal deletions, then genome doubling and subsequent accumulation of subclonal gains and amplifications.]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[A recent Nature study delineates a stepwise genomic evolution during pancreatic cancer development, employing an engineered mutant Kras and heterozygous Trp53 mouse model that identifies cells undergoing Trp53 loss of heterozygosity (LOH). Genetic progression post-Trp53 LOH involves clonal deletions, then genome doubling and subsequent accumulation of subclonal gains and amplifications.]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[A recent Nature study delineates a stepwise genomic evolution during pancreatic cancer development, employing an engineered mutant Kras and heterozygous Trp53 mouse model that identifies cells undergoing Trp53 loss of heterozygosity (LOH). Genetic progression post-Trp53 LOH involves clonal deletions, then genome doubling and subsequent accumulation of subclonal gains and amplifications.]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[A recent Nature study delineates a stepwise genomic evolution during pancreatic cancer development, employing an engineered mutant Kras and heterozygous Trp53 mouse model that identifies cells undergoing Trp53 loss of heterozygosity (LOH). Genetic progression post-Trp53 LOH involves clonal deletions, then genome doubling and subsequent accumulation of subclonal gains and amplifications.]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[A recent Nature study delineates a stepwise genomic evolution during pancreatic cancer development, employing an engineered mutant Kras and heterozygous Trp53 mouse model that identifies cells undergoing Trp53 loss of heterozygosity (LOH). Genetic progression post-Trp53 LOH involves clonal deletions, then genome doubling and subsequent accumulation of subclonal gains and amplifications.]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[A recent Nature study delineates a stepwise genomic evolution during pancreatic cancer development, employing an engineered mutant Kras and heterozygous Trp53 mouse model that identifies cells undergoing Trp53 loss of heterozygosity (LOH). Genetic progression post-Trp53 LOH involves clonal deletions, then genome doubling and subsequent accumulation of subclonal gains and amplifications.]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[A recent Nature study delineates a stepwise genomic evolution during pancreatic cancer development, employing an engineered mutant Kras and heterozygous Trp53 mouse model that identifies cells undergoing Trp53 loss of heterozygosity (LOH). Genetic progression post-Trp53 LOH involves clonal deletions, then genome doubling and subsequent accumulation of subclonal gains and amplifications.]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221119201544&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[A recent Nature study delineates a stepwise genomic evolution during pancreatic cancer development, employing an engineered mutant Kras and heterozygous Trp53 mouse model that identifies cells undergoing Trp53 loss of heterozygosity (LOH). Genetic progression post-Trp53 LOH involves clonal deletions, then genome doubling and subsequent accumulation of subclonal gains and amplifications.]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221119201544&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone]]></title>
        <id>pubmed:36379206</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36379206/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[A recent Nature study delineates a stepwise genomic evolution during pancreatic cancer development, employing an engineered mutant Kras and heterozygous Trp53 mouse model that identifies cells undergoing Trp53 loss of heterozygosity (LOH). Genetic progression post-Trp53 LOH involves clonal deletions, then genome doubling and subsequent accumulation of subclonal gains and amplifications.]]></summary>
        <author>
            <name>Bogang Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221117201522&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221116201100&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution]]></title>
        <id>pubmed:36376909</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36376909/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221115201214&amp;v=2.17.8"/>
        <updated>2022-11-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aneuploidy, chromosomal instability, somatic copy-number alterations, and whole-genome doubling (WGD) play key roles in cancer evolution and provide information for the complex task of phylogenetic inference. We present MEDICC2, a method for inferring evolutionary trees and WGD using haplotype-specific somatic copy-number alterations from single-cell or bulk data. MEDICC2 eschews simplifications such as the infinite sites assumption, allowing multiple mutations and parallel evolution, and does...]]></summary>
        <author>
            <name>Tom L Kaufmann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221201200047&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221119201545&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221117201524&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221116201100&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221115201214&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Probing Clonal Hematopoiesis in Liquid Biopsy]]></title>
        <id>pubmed:36374003</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36374003/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221114201139&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased use of liquid biopsy to pinpoint actionable genomic alterations in cancer has been accompanied by a rise in the incidental detection of clonal hematopoiesis. Its clinical significance remains unclear, however, as well as how best to risk-stratify patients for further evaluation and, if necessary, treatment.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221201200049&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221201200049&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221119201544&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221119201544&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221117201522&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221117201522&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221116201100&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221116201100&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221115201214&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221115201214&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase]]></title>
        <id>pubmed:36373660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36373660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221114201139&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence...]]></summary>
        <author>
            <name>Kilannin Krysiak</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028)]]></title>
        <id>pubmed:36372873</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36372873/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221114201139&amp;v=2.17.8"/>
        <updated>2022-11-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CSF ctDNA exhibited unique genetic profiles of brain metastases, and dynamic changes in CSF ctDNA could better predict intracranial tumor responses and track clonal evolution during treatment in NSCLC patients with brain metastases.]]></summary>
        <author>
            <name>Meichen Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>Anupriya S</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>Anupriya S</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>Anupriya S</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>Anupriya S</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>Anupriya S</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>S Anupriya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>S Anupriya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>S Anupriya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>S Anupriya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>S Anupriya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221119201544&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>S Anupriya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>S Anupriya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221117201522&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>S Anupriya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221116201100&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>S Anupriya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221115201214&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>S Anupriya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221114201139&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>S Anupriya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and expansion associated with therapy resistance and relapse of Colorectal Cancer]]></title>
        <id>pubmed:36371022</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36371022/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221113201202&amp;v=2.17.8"/>
        <updated>2022-11-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal evolution. Multiple genes and pathways have a role in tumor initiation and progression. The gradual accumulation of genetic and epigenetic processes leads to the establishment of adenoma and cancer. The important 'driver' mutations in tumor suppressor genes (such as TP53, APC, and SMAD4) and oncogenes (such as KRAS, NRAS, MET, and PIK3CA) confer selective growth advantages and cause CRC advancement....]]></summary>
        <author>
            <name>S Anupriya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221119201545&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221117201524&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221116201100&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221115201214&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221114201139&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221113201202&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221112201337&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence]]></title>
        <id>pubmed:36358655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221111201407&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansions of large granular lymphocytes (LGL) have been reported in a wide spectrum of conditions, with LGL leukemia (LGLL) being the most extreme. However, the boundaries between LGLL and LGL clones are often subtle, and both conditions can be detected in several clinical scenarios, particularly in patients with cytopenias. The intricate overlap of LGL clonal expansion with other disease entities characterized by unexplained cytopenias makes their classification challenging. Indeed,...]]></summary>
        <author>
            <name>Giulia Calabretto</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221119201544&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221117201522&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221116201100&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221115201214&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221114201139&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221113201202&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221112201337&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma]]></title>
        <id>pubmed:36358353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36358353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221111201407&amp;v=2.17.8"/>
        <updated>2022-11-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastomas are incurable primary brain tumors harboring a heterogeneous landscape of genetic and metabolic alterations. Longitudinal imaging by MRI and [^(18)F]FET-PET measurements enable us to visualize the features of evolving tumors in a dynamic manner. Yet, close-meshed longitudinal imaging time points for characterizing temporal and spatial metabolic alterations during tumor evolution in patients is not feasible because patients usually present with already established tumors. The...]]></summary>
        <author>
            <name>Hannes Becker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221130201253&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221129200557&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221128200439&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221119201545&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221119201545&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221119201545&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221117201524&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221117201524&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221117201524&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221116201100&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221116201100&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221116201100&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221115201214&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221115201214&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221115201214&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221114201139&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221114201139&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221114201139&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221113201202&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221113201202&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221113201202&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221112201337&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221112201337&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221112201337&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221111201407&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221111201407&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221111201407&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and cardiovascular disease: deciphering interconnections]]></title>
        <id>pubmed:36355225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36355225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221110201819&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by...]]></summary>
        <author>
            <name>Anna Stein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[2022 Jeffrey M. Hoeg Award Lecture: Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease]]></title>
        <id>pubmed:36353993</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353993/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221110201819&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronologic age is the dominant risk factor for coronary artery disease but the features of aging promoting coronary artery disease are poorly understood. Advances in human genetics and population-based genetic profiling of blood cells have uncovered the surprising role of age-related subclinical leukemogenic mutations in blood cells, termed "clonal hematopoiesis of indeterminate potential," in coronary artery disease. Such mutations typically occur in DNMT3A, TET2, ASXL1, and JAK2. Murine and...]]></summary>
        <author>
            <name>Pradeep Natarajan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recurrent missense variants in clonal hematopoiesis-related genes present in the general population]]></title>
        <id>pubmed:36353970</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36353970/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20221110201819&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) consists in an abnormal expansion of a hematopoietic stem cell bearing an advantageous somatic variant. A survey of known recurrent somatic missense variants in DNMT3A, SF3B1, SRSF2 and TP53, some of the most prominent genes underlying CH of indeterminate potential (CHIP), in gnomAD non-cancer database shows the presence of 73 variants. Many of them reach frequencies higher than 0.01% in various populations and, in many cases, are enriched in specific populations....]]></summary>
        <author>
            <name>Olivier Ariste</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221127200227&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221126200943&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221119201544&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221117201522&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221116201100&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221115201214&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221114201139&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221113201202&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221112201337&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221111201407&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers]]></title>
        <id>pubmed:36354097</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36354097/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221110201819&amp;v=2.17.8"/>
        <updated>2022-11-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The interplay between microRNAs (miRNAs) and pluripotency transcription factors (TFs) orchestrates the acquisition of cancer stem cell (CSC) features during the course of malignant transformation, rendering them essential cancer cell dependencies and therapeutic vulnerabilities. In this review, we discuss emerging themes in tumor heterogeneity, including the clonal evolution and the CSC models and their implications in resistance to cancer therapies, and then provide thorough coverage on the...]]></summary>
        <author>
            <name>Radhakrishnan Vishnubalaji</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour1-3. Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive4,5. Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221125200054&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour1-3. Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive4,5. Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221124200507&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour1-3. Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive4,5. Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221123201010&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour1-3. Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive4,5. Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221122200439&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour1-3. Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive4,5. Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221121201257&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour^(1-3). Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive^(4,5). Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth patterns, and...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221120201223&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221119201544&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour^(1-3). Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive^(4,5). Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth patterns, and...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221119201544&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour^(1-3). Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive^(4,5). Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth patterns, and...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221118201229&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221117201522&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour^(1-3). Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive^(4,5). Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth patterns, and...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221117201522&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221116201100&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour^(1-3). Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive^(4,5). Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth patterns, and...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221116201100&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221115201214&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour^(1-3). Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive^(4,5). Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth patterns, and...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221115201214&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221114201139&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour^(1-3). Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive^(4,5). Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth patterns, and...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221114201139&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221113201202&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour^(1-3). Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive^(4,5). Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth patterns, and...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221113201202&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221112201337&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour^(1-3). Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive^(4,5). Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth patterns, and...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221112201337&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221111201407&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour^(1-3). Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive^(4,5). Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth patterns, and...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221111201407&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomics maps the structure, nature and evolution of cancer clones]]></title>
        <id>pubmed:36352222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36352222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221110201819&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genome sequencing of cancers often reveals mosaics of different subclones present in the same tumour^(1-3). Although these are believed to arise according to the principles of somatic evolution, the exact spatial growth patterns and underlying mechanisms remain elusive^(4,5). Here, to address this need, we developed a workflow that generates detailed quantitative maps of genetic subclone composition across whole-tumour sections. These provide the basis for studying clonal growth patterns, and...]]></summary>
        <author>
            <name>Artem Lomakin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221110201819&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resistance Mechanisms to Anti-EGFR Therapy in <em>RAS/RAF</em> Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy]]></title>
        <id>pubmed:36351210</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/36351210/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20221109201530&amp;v=2.17.8"/>
        <updated>2022-11-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings support a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with EGFRi, with a greater predominance of acquired MAPK mutations after single-agent EGFRi. The proposed model has implications for prospective studies evaluating EGFRi rechallenge strategies guided by acquired MAPK mutations, and highlights the need to address transcriptional mechanisms of resistance.]]></summary>
        <author>
            <name>Christine M Parseghian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nodal interferon exposure drives tumour-specific tolerance]]></title>
        <id>72a3a11d39c217b1a80cbb551444e6f6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1533878403463405569"/>
        <updated>2022-06-06T18:28:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nodal interferon exposure drives tumour-specific tolerance https://t.co/FT4NeBcFTg pic.twitter.com/NRHkVDUsOr
 NatureReviewsCancer (@NatureRevCancer) June 6, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VIBConferences: #Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.Registration Deadline: Thursday 2 June. Read more]]></title>
        <id>bb6bc242bcbc356c4a38db850e74d812</id>
        <link href="https://twitter.com/VIBConferences/status/1531132720952266752"/>
        <updated>2022-05-30T04:37:42.000Z</updated>
        <summary type="html"><![CDATA[#Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.
Registration Deadline: Thursday 2 June. Read more https://t.co/cc0HC5cj6W pic.twitter.com/u8LFuzBbsV
 VIB Conferences (@VIBConferences) May 30, 2022]]></summary>
        <author>
            <name>@VIBConferences</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy]]></title>
        <id>ed6c996dc1a718afb523de6229a53131</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530198403686072320"/>
        <updated>2022-05-27T14:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy https://t.co/wjuHplkpof pic.twitter.com/1SoKYhRsPO
 NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content ]]></title>
        <id>d15a3a4b24853812d7fa21fd56de5815</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530174481313972224"/>
        <updated>2022-05-27T13:10:00.000Z</updated>
        <summary type="html"><![CDATA[Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content 
 https://t.co/Fo6XRWV3OZ@natrescancer pic.twitter.com/rbxRPqLV6g
 NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@UlrikeHarjes: This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer:  do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest]]></title>
        <id>fe13755a2693ea65459e5e21df097d2a</id>
        <link href="https://twitter.com/UlrikeHarjes/status/1529747629936193537"/>
        <updated>2022-05-26T08:53:50.000Z</updated>
        <summary type="html"><![CDATA[This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer: https://t.co/p3Y2cdNhco
I do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest https://t.co/qWH2dTv8j9
 Ulrike Harjes (@UlrikeHarjes) May 26, 2022]]></summary>
        <author>
            <name>@UlrikeHarjes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Developing dietary interventions as therapy for cancer]]></title>
        <id>9ba5279424b31b0122a4ae20c18e6d03</id>
        <link href="https://twitter.com/NatureRevCancer/status/1529516411059437568"/>
        <updated>2022-05-25T17:35:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Developing dietary interventions as therapy for cancer https://t.co/ijuqctk1wJ pic.twitter.com/KHPpMKnCFa
 NatureReviewsCancer (@NatureRevCancer) May 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Digging for treasures in the tumour interactome]]></title>
        <id>611d40f2e6ea2796b028bebda41a86dd</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526928478490095616"/>
        <updated>2022-05-18T14:11:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Digging for treasures in the tumour interactome https://t.co/NhHYAwUgLE
 NatureReviewsCancer (@NatureRevCancer) May 18, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: As part of our overall commitment to diversity, equity and inclusion at Springer Nature, wed like to better understand what DEI means within the global research community. Take the survey here]]></title>
        <id>9590a971b00448cd312078183965b21d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526560254091313156"/>
        <updated>2022-05-17T13:48:21.000Z</updated>
        <summary type="html"><![CDATA[As part of our overall commitment to diversity, equity and inclusion at Springer Nature, wed like to better understand what DEI means within the global research community. Take the survey here https://t.co/03yLiUxFTq
 NatureReviewsCancer (@NatureRevCancer) May 17, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT   where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial ]]></title>
        <id>aa38ff4245b93e964773f191844ddc7a</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524772831904509953"/>
        <updated>2022-05-12T15:25:46.000Z</updated>
        <summary type="html"><![CDATA[Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT   where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial  https://t.co/VbyoUJmTRJ
 NatureReviewsCancer (@NatureRevCancer) May 12, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tools for the next generation]]></title>
        <id>65aca76b9f794aaa668d84ad32dca4a0</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524068259712036864"/>
        <updated>2022-05-10T16:46:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tools for the next generation https://t.co/lEzTPFYDf5
 NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon]]></title>
        <id>afa9b6784b4ccc7c05ed4efd26ddfb2d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524022709386190856"/>
        <updated>2022-05-10T13:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon https://t.co/XXT0c9SAYX
 NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VarunVenkatara2: Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter]]></title>
        <id>43e2d5ccebc9030f737d656f47ac9d98</id>
        <link href="https://twitter.com/VarunVenkatara2/status/1520050291986604033"/>
        <updated>2022-04-29T14:40:05.000Z</updated>
        <summary type="html"><![CDATA[Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter https://t.co/S55cKTGNFd
 Varun Venkataramani (@VarunVenkatara2) April 29, 2022]]></summary>
        <author>
            <name>@VarunVenkatara2</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! An inhospitable site]]></title>
        <id>9f6b8644378881f4c2e6b6833c93fc2f</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020349068316673"/>
        <updated>2022-04-29T12:41:06.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! An inhospitable site https://t.co/0dvqIKCWxh pic.twitter.com/PtY8J9Fz7r
 NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Disconnecting multicellular networks in brain tumours]]></title>
        <id>f6d91efcd60dae769e2722585bdfa8df</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020340201598978"/>
        <updated>2022-04-29T12:41:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Disconnecting multicellular networks in brain tumours https://t.co/LJrzy8bRma pic.twitter.com/CO7BnooP0r
 NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.]]></title>
        <id>76e3b436bc8e43ad21366a80c120e395</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519678964364623872"/>
        <updated>2022-04-28T14:04:34.000Z</updated>
        <summary type="html"><![CDATA[Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.
 https://t.co/vQwHFJhpwv@natrescancer pic.twitter.com/6kYgjRYhdT
 NatureReviewsCancer (@NatureRevCancer) April 28, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@tmurraystewart: Our latest publication on #polyamines is online!@HopkinsMedicine]]></title>
        <id>fdf224ea293cdf039086d16e5699a59a</id>
        <link href="https://twitter.com/tmurraystewart/status/1519413460978704384"/>
        <updated>2022-04-27T20:29:33.000Z</updated>
        <summary type="html"><![CDATA[Our latest publication on #polyamines is online!@HopkinsMedicine https://t.co/ehRGgN1w9R
 Tracy Murray Stewart (@tmurraystewart) April 27, 2022]]></summary>
        <author>
            <name>@tmurraystewart</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity]]></title>
        <id>4f43226ec4dc8e531ff6e64a9c5ab8e6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519381375874265088"/>
        <updated>2022-04-27T18:22:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity https://t.co/YCJX1hRQLO pic.twitter.com/zRUCRNXyxH
 NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.]]></title>
        <id>a44ed79b9f76aad377b9272fb392f553</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519317944995569664"/>
        <updated>2022-04-27T14:10:00.000Z</updated>
        <summary type="html"><![CDATA[NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.
 https://t.co/JTUhX0DHQ1@natrescancer pic.twitter.com/2PdCmsDu2p
 NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino  @natrescancer @Columbia]]></title>
        <id>06ff7641d8f5fcc0dff91f835ac3bbc1</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518967636561956865"/>
        <updated>2022-04-26T14:58:00.000Z</updated>
        <summary type="html"><![CDATA[In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino
 https://t.co/GeTVCMJQsp @natrescancer
 @Columbia pic.twitter.com/ZXW6A0Fe0c
 NatureReviewsCancer (@NatureRevCancer) April 26, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tracking dormant disseminated tumour cells]]></title>
        <id>96b2ddff4eb269cf343213c6a1b1ce95</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518563607440621569"/>
        <updated>2022-04-25T12:12:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tracking dormant disseminated tumour cells https://t.co/kSXyWAvCxF
 NatureReviewsCancer (@NatureRevCancer) April 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
</feed>